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CHAPTER I
INTRODUCTION

Left ventricular hypertrophy (LVH) in response to hemodynamic overload is associated
with increased morbidity and mortality due to progressive left ventricular systolic
dysfunction, impaired diastolic relaxation, irreversible muscle injury and the ultimate
development of congestive heart failure (CHF). Whereas a great deal has been learned over
the past 10 years regarding the mechanisms leading to the development of LVH (Chien et
al., 1991 ), little is currently known about the cellular and molecular events responsible for
the transition from apparently stable hypertrophy to global left ventricular dysfunction
(LeJemtel et al., 1993).

One third of all patients with CHF have LV diastolic dysfunction without significant
systolic dysfunction (Fouad, et al., 1984). The mechanisms responsible for the diastolic
dysfunction in LVH and CHF are largely unknown, but are likely to be multiple. These
may include changes in dynamic factors which modulate the inactivation of systolic force
(such as alterations in intracellular calcium ([Ca2+]i) handling during myocardial relaxation),
and changes in the composition of the LV myocardium which affect LV compliance (such
as tissue fibrosis).
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Myocardial relaxation is in part dependent upon the activity of the sarcoplasmic
reticulum Ca2+ A TPase (SERCA2), which is a membrane enzyme responsible for pumping
[Ca2li back into the sarcoplasmic reticulum (SR) during diastole. In both humans and
experimental animals with pressure overload LVH and CHF, SERCA2 mRNA and protein
levels have been found to be significantly decreased (Komuro et al., 1989, de la Bastie et
al., 1990, Levtsky et al., 1991, Arai et al., 1993, Hasefuss et al., 1994 and Matsui et al.,
1995). A decrease in SERCA2 activity would be expected to produce prolongation of the
[Ca2+]i transient, and secondarily to cause delayed myocardial relaxation. Therefore, it is
conceivable that the observed reduction in SERCA2 activity may play a causal role in the
development of diastolic dysfunction seen in pressure overload cardiac hypertrophy, and
may also be involved in the deleterious transition to CHF. It should be pointed out,
however, that not all forms of human CHF demonstrate reduced SERCA2 expression. For
instance, Movsesian et al (1994) found that SR Ca2+ ATPase protein content was not
diminished in patients with idiopathic dilated cardiomyopathy and end-stage CHF,
indicating that down-regulation of SR Ca2+ A TPase is not part of the molecular
pathophysiology of this disorder. Thus, the role of SR function in LVH and CHF warrants
further investigation. Furthermore, there is no evidence to demonstrate that a decrease in
2
SR Ca + ATPase activity directly correlates with the deterioration of hemodynamic function
that occurs during the development of pressure overload hypertrophy. This is one of the
specific aims of this dissertation study.
A great deal of information is currently available about the SR Ca2+A TPase gene family
and the SERCA2 gene. It is known that SERCA2 gene expression is tissue-specific and
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developmentally regulated (Arai et al., 1992, Lompre 1991, Fisher et al., 1992, Antoon et
al., 1995, Mnger et al., 1994, Mahony et al., 1986). However, little is known about the
molecular mechanisms involved in the regulation of SERCA2 gene expression. Thyroid
hormone is the only well studied factor known to regulate cardiac SERCA2 gene expression
at the transcriptional level (Arai et al., 1991, Nagai et al., 1989, Rohrer et al., 1988, 1991,
Ojamaa et al., 1992, Zarain-Herzberg et al., 1994). Interestingly, the reduced SERCA2
mRNA levels observed in pressure-overloaded, hypertrophied hearts occurs in the presence
of normal circulating levels of thyroid hormones, indicating that other factors (including a
direct effect of mechanical load) may regulate SERCA2 gene expression in vivo. At the
present time, it remains largely unknown which signal transduction pathways are involved
in the regulation of SERCA2 gene expression during LVH progression.
Obviously, it is difficult to precisely identify the manner in which mechanical stimuli
regulate SERCA2 gene expression in the pressure overloaded and failing heart in vivo. It is
even more complicated to identify second messengers that may be involved in transducing
mechanical signals from the cell surface to the nucleus during the development of pressure
overload LVH. To understand the mechanisms by which hemodynamic overload alters the
expression of cardiac genes, pressure overload hypertrophy in vivo has been mimicked by
stimulation of cultured cells in vitro with hormonal (Simpson et al., 1991), humoral (Qi et
al., 1994, Parker et al., 1990), or mechanical factors (Samarel and Engelmann, 1991,
Komuro et al., 1991 ). Primary cultures of neonatal ventricular myocytes have been widely
used to identify the signal transduction pathways involved in the development of cardiac
hypertrophy. A growing body of evidence has demonstrated that protein kinase C (PKC)
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(Kariya et al., 1991, Shubeitha et al., 1992, Samarel and Engelmann, 1991, Qi et al., 1994)
plays a very important roles in the regulation of cardiac gene expression during myocyte
hypertrophy.

Other signal transduction pathways such as Ca2+/Calmodulin-dependent

protein kinase II (CaMK) may also be involved in regulating gene expression in cardiac
hypertrophy (McDonough and Glembotski, 1992, 1994). Whether these factors are also
involved in the regulation of SERCA2 gene expression during pressure overload
hypertrophy is not known, but is specifically addressed in this dissertation work.
The main focus of my dissertation work is to evaluate the role of SERCA2 gene
expression in the development of pressure overload LVH and CHF and to determine the
role of mechanical activity and PKC in the regulation of SERCA2 gene expression. These
aims are accomplished by experiments at three levels of investigation.
Firstly, I developed an animal model of pressure overload LVH (abdominal aortic
coarctation (abdominal AoC) in Sprague-Dawley rats) that could be used to evaluate
SERCA2 gene regulation during the transition from compensated LVH to decompensated
CHF. This transition period was identified by hemodynamic indices of LV systolic and
diastolic function measured in the intact animal. Hemodynamic measurements were then
correlated with alterations in LV tissue composition (including the level of expression of
SERCA2 mRNA and protein) in the hypertrophied myocardium.
Secondly, primary cultures of neonatal rat ventricular myocytes were used to study the
potential cellular and molecular mechanisms responsible for the regulation of SERCA2
gene expression during cardiac myocyte hypertrophy and atrophy. I examined the effects
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that alterations in mechanical activity and PKC activity have on myocyte growth and the
expression of SERCA2 mRNA and protein levels in these cultured heart cells.
Finally, to further investigate the molecular mechanisms involved in SERCA2 gene
expression, a transient transfection assay and message stability analysis were used to
determine whether the changes in SERCA2 mRNA levels induced by changes in
mechanical activity and PKC activity were mediated by changes in the rate of SERCA2
gene transcription or were due to changes in SERCA2 mRNA stability.
Thus, the combination of a variety of approaches provides us with additional useful
information about the regulation of SERCA2 gene expression during LVH and the
transition to CHF.

CHAPTER II
REVIEW OF RELATED LITERATURE

A. INTRODUCTION

According to the Framingham Study, a 30-year longitudinal study of cardiovascular risk
among residents of Framingham, Massachusetts, arterial hypertension is the single most
important etiologic factor in the development of symptomatic CHF. Furthermore, the risk
of developing CHF increases 6-18 fold in the presence of electrocardiographic and/or
echocardiographic evidence of LVH (Kannel et al., 1987). Thus the development of LVH
in response to arterial hypertension and other forms of hemodynamic overload is a
harbinger for the subsequent development of significant cardiovascular morbidity and
mortality. However, the changes which trigger the transition from stable LVH to overt CHF
are poorly characterized.
In response to increased hemodynamic load, the heart alters its function, increasing its

muscle mass and qualitatively and quantitatively changing its gene expression.

It is

apparent that one of the alterations in cardiac gene expression that accompanies the
hypertrophic process is a reduction in the expression of the SR Ca ATPase (SERCA2)
6

7

mRNA and protein levels of this calcium transporter are down-regulated during pressure
overload hypertrophy and CHF in a variety of experimental animal models of hemodynamic
overload, and in human CHF. This decrease in SERCA2 gene expression may be at least in
2

part the cause of the abnormal Ca
overloaded and failing hearts.

+

handling and slowed cardiac relaxation in pressure

To date, a thorough investigation of SERCA2 gene

regulation and the potential cellular and molecular mechanisms involved in its regulation
during LVH progression have not been conducted.
This chapter is designed to furnish the reader with a basic understanding of the
physiology and molecular biology of cardiac hypertrophy, and with information regarding
the molecular biology of SR Ca ATPase and its regulation during pressure overload
hypertrophy and CHF.

Literature regarding the use of cell culture models of cardiac

hypertrophy is also reviewed, as these cell culture systems have greatly aided our
understanding of potential triggers for the development of cardiac hypertrophy. In general,
two types of triggers involved in the development of pressure overload hypertrophy in vivo
have been intensively investigated in cultured cells. These are mechanical triggers such as
passive stretch and active contraction; and trophic triggers such as peptide-derived growth
factors (including fibroblast growth factors, transforming growth factors, angiotensin II, and
endothelin), and adrenoreceptor activation. The accumulated data suggest the involvement
of PKC-dependent signaling pathways in the transduction of both mechanical and humoral
signals leading to myocyte hypertrophy. A growing body of evidence has demonstrated that
several isoenzymes of PKC can be activated by different hypertrophic stimuli. Therefore in
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this chapter, the structure and function of the various cardiac PKC isoenzymes are also
reviewed in the context of their potential role in cardiac hypertrophy signal transduction.

B. HEMODYNAMIC OVERLOAD INDUCED CARDIAC HYPERTROPHY

1. General Concept of Cardiac Hypertrophy.

During postnatal development, the cardiac myocyte rapidly loses its ability to
proliferate, and subsequent growth of the heart is dependent upon enlargement of preexisting muscle cells. Under normal conditions, an equilibrium is attained in which cardiac
muscle mass matches the workload that is imposed on the heart. When subjected to a
chronic increase in hemodynamic load (in the form of either pressure or volume overload),
the myocardium adapts by increasing its muscle mass.

For reasons incompletely

understood, there appears to be a limit to this compensatory response, and long-standing
hypertrophy can often result in the subsequent development of CHF, which is a
pathophysiological condition characterized by the inability of the heart to pump blood at a
rate commensurate with the requirements of the metabolizing tissues. Therefore, LVH is a
common consequence of hypertension and other forms of hemodynarnic overload, and LVH
is an independent risk factor for the subsequent development of cardiovascular morbidity
and mortality.

9

LVH is characterized by myocyte hypertrophy and hypertrophy/hyperplasia of
nonmyocyte cells. Myocyte hypertrophy is cell enlargement accompanied by a generalized
increase in protein content per cell. This generalized increase in cellular protein content
results from an overall increase in the rate of protein synthesis, which is associated with
increases in the amounts of both messenger and ribosomal RNA. The increase in total RNA
content is based on increases in the rate of DNA transcription as well as RNA stability
(McDermott et al., 1989). Cardiac hypertrophy is also characterized by activation of a new
program of gene expression. These genes can be divided into two classes: immediate-early
(IE) response genes and late-response genes.

During the last decade, a wealth of

information has been obtained concerning the transient expression of IE genes in the heart
in response to work overload.

IE genes include a number of proto-oncogenes, which

encode an intricately inter-connected network of proteins whose function is also crucial to
normal growth and differentiation (Bishop, 1987, Nulvagh et al., 1988, Weinberg, 1989,
Schneider et al., 1991). An example of IE gene induction is the enhanced expression of cfos and c-myc in the rat heart in vivo in response to thoracic aortic banding (Komuro et al.,

1988).

These IE genes encode nuclear transcription factors, whose own transcription

requires no new protein synthesis. The induction of proto-oncogene transcription may
initiate the earliest steps in altered gene expression during hemodynamic overload. In
addition, there is increased expression of a number of stress proteins in the heart in response
to hemodynamic overload (Delcayre et al., 1988), whose function in the hypertrophic
response remains obscure.
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In contrast to the relatively transient expression of proto-oncogenes, cardiac myocytes

respond to hemodynamic overload with a sustained alteration in the expression of many
late-response genes, including the cardiac contractile protein genes. The contractile unit of
the myocardium is the sarcomere, which is composed of seven major proteins and several
minor ones. All of these major proteins have multiple isoforms, and the transcription rates
of some isoforms are selectively increased in cardiac hypertrophy. In general, this response
is characterized by the re-expression of contractile protein isoforms which are
predominantly expressed in the immature heart (Nadal-Ginard and Mahdavi, 1989, Morkin,
1987, and Schiaffino et al., 1989.). As a late-response gene, cardiac myosin heavy chain
(MHC), is best studied both at the molecular and tissue levels (for review see Nadal-Ginard
and Mahdavi, 1989).

In adult rodents and other small mammals, cardiac myocytes

predominantly express a cardiac-specific, fast MHC isoform (MHC-a). In response to
hemodynamic overload, the cardiac/slow skeletal muscle isoform (MHC-J3) is induced
(Mercadier, et al., 1981, Klein et al., 1992). Of note, MHC-J3 is normally expressed at high
levels only in the fetal and neonatal heart. Actin, another important cardiac contractile
protein, also exists as 3 isoforms (skeletal, cardiac and smooth muscle a-actin). In pressure
overloaded rat heart, the skeletal a-actin isoform is up-regulated, with unaltered or
decreased cardiac a-actin expression (Schwartz et al., 1986, 1993 and Izumo et al., 1988).
Since skeletal a-actin is highly expressed in utero, its re-expression during pressure
overload represents another example in which a "fetal program" of gene expression is
reactivated by hemodynamic overload. Another actin isoform, smooth a-actin normally
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expressed in vascular smooth muscle, was found to be reactivated with pressure overload
hypertrophy, and the high levels of smooth muscle actin mRNA in the hypertrophied
myocardium strongly suggest that this isoform is present in the myocytes (Black et al.,
1991). The two other types of cardiac myosin subunits, myosin light chains (MLC) 1and2,
both exist as two isoforms, atrial and ventricular. The atrial isoform ALCl increases in
several forms of ventricular hypertrophy (Boheler and Schwartz, 1992), whereas the
ventricular types VLC 1 and VLC2 are re-expressed in pressure-overloaded human atria
(Cummins, 1982).

This reprogramming of cardiac myocyte gene expression by

hemodynamic overload is not limited to contractile proteins. Ventricular myocytes also reexpress atrial natriuretic factor (ANF), a gene whose expression is lost during normal
postnatal cardiac development (Chien et al., 1991, Lattion et al., 1986, Knowlton et al.,
1991).

In contrast to these up-regulated genes, mRNA levels encoding some genes,

including the gene encoding the SR Ca ATPase, are down-regulated in response to pressure
overload. Evidence documenting that SERCA2 mRNA and protein levels decrease during
pressure overload hypertrophy and heart failure are reviewed in a separate section of this
chapter.
The muscle cell compartment of myocardial tissue is not the only cell type that is
affected during pressure overload. Hypertrophy and hyperplasia of nonmyocyte components
also occurs in pathological forms of cardiac hypertrophy. The increased expression of
collagen genes and remodeling of the cardiac extracellular matrix is another characteristic of
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overload-induced cardiac hypertrophy, and these alterations may also contribute to the
deterioration of cardiac function in the hypertrophied and failing heart.

2. In Vivo Animal Models.
Many models of cardiac hypertrophy produced in the intact experimental animal have
been used to simulate the human condition. Each model has unique advantages as well as
disadvantages which are relevant to the interpretation of the acquired experimental data
(Table 1). Characteristics of the growth responses vary widely, depending on experimental
conditions. Variables commonly recognized are the severity, duration and type of overload
(i.e., pressure vs. volume), and the rate at which the hemodynarnic overload is applied (i.e.,
acute vs. gradual), as well as the age and species of the animal. A major complication in the
study of in vivo models of pathological cardiac hypertrophy is the change in the body weight
of the animal. Normal growth can be affected by surgical trauma, nutritional, and other
factors. To evaluate the degree of hypertrophy, in such cases, one must rely not on the size
of the heart but on its ratio to body size. The second complication arises when the overload
is accompanied by injury to the blood vessels and heart. Coarctation of either the thoracic
and abdominal aorta in juvenile animals are the most commonly used methods to produce
pressure overload LVH. Both surgical approaches produce increased LV afterload, induce
substantial LVH, and generate the pressure-overload phenotype which simulates to some
extent LVH in humans.

Abdominal aortic coarctation (AoC) but not thoracic AoC is

associated with systemic hypertension (Weinberg et al., 1994). Whereas abdominal AoC
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produces no cardiac myocyte necrosis, thoracic AoC can cause severe muscle damage, and
is also associated a higher perioperative mortality. Therefore, abdominal AoC is a better
model to mimic chronic human hypertension. However, thoracic AoC has the advantage
that hypertension-induced release of neurohumoral agents, growth factors, and other
substances into the circulation from noncardiac tissues is limited or prevented.
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TABLEl
Jn vivo animal models for studying hemodynamic overload induced cardiac hypertrophy.

Ptessure nverJoau

'Volume overload

Aortic stenosis

Arteriovenous fistula

Thoracic aortic coarctation

(rat, Dart and Holloszy, 1969)

(rat, Takahashi et al., 1992), (ferret, Wang et al., 1994)
(cat, Bailey & Houser, 1992)
Abdominal aortic coarctation
(rat, Nagai et al., 1989) (pig, Dhalla et al., 1984)
(guinea pig, Cory et al., 1994)
··--·---·~-···-··-··········~---------·------·--·--·--·--------+-------·-·-·---·----·----·

Pulmonary artery stenosis

Bradycardia

(cat, Shlafer et al., 1978), (rat, Julian et al., 1981), (rabbit, Matsui

(dog, Brockman, 1965)

et al., 1995), (ferret, Gwathmey & Morgan, 1985)
Hypertension

Sideropenic anemia

Renal ischemia (rat, Goldblatt et al., 1934) (guinea pig,

(rat, Bartsova et al., 1969)

Naqvi and Macleod, 1994)
Nephrectomy (rat, Grollman, 1944)
Nephrectomy+DOCA+salt (rat, Bartsova et al., 1969)

Aortic insufficiency

Aldosterone+salt (rat, Garwitz and Jones, 1981)

(rabbit, Hatt et al., 1970)

Spontaneous SHR (rat, LeJemtel et al., 1993b)
Spontaneous, Dahl, salt-sensitive (rat, pfeffer et al., 1984)
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c.

MECHANISMS RESPONSIBLE FOR THE CHANGES IN CARDIAC

PERFORMANCE DURING THE DEVELOPMENT OF PRESSURE OVERLOAD
LVH

Functional abnormalities in myocardial contraction and relaxation are commonly
observed in patients with LVH due to hypertensive and valvular heart diseases, and these
abnormalities have been successfully reproduced in a variety of experimental animal models
of pressure overload LVH.

These include a reduction in the velocity of contraction,

prolonged ejection, and delayed relaxation (Capasso et al., 1990). Impaired contractile
function can also be demonstrated in isolated cardiac muscle strips and perfused heart
preparations from animals with experimentally induced pressure overload LV or RV
hypertrophy (Bing et al., 1971, Alpert and Mulieri, 1982, Bentivegna et al., 1991). These
abnormalities include prolongation of isometric contraction, an increase in the time to peak
tension development, a decrease in isotonic shortening velocity, and decreased maximum
isometric force. There is now considerable evidence to indicate that ventricular diastolic
properties are also impaired in experimental animals and humans with pressure overload
(Fouad, 1987, Lorell et al., 1990, Siri et al., 1989, Swynghedauw et al., 1992).
Abnormalities in left ventricular diastolic function can be broadly classified in two groups:
(1) those related to left ventricular relaxation and early diastolic filling; and (2) those related

to altered passive pressure-volume characteristics and reduced compliance. Since the extent
of cardiac muscle activation with each systole is dependent on the completeness of
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relaxation during the preceding diastole; and ventricular systolic function is dependent upon
adequate ventricular diastolic filling, decreased diastolic function may thus contribute to the
systolic abnormalities in the pressure-overload hypertrophied heart.

1. MHC Isoenzyme Switching is Partly Responsible for Contractile Dysfunction
During Pressure Overload Hypertrophy.

The early search for biochemical correlates of cardiac hypertrophy centered around
attempts to relate myosin ATPase activity to physiological function. Early studies using
rodent models of LVH demonstrated a close correlation between the maximum velocity of
contraction (Vmax) and the specific activity of the Ca2+ activated, myosin ATPase (Pope, et
al., 1980, Schwartz, et al., 1981). Subsequent studies revealed that cardiac myosin heavy
chain (MHC) was composed of two different isoforms, which are the products of two
closely linked genes. MHC-a, which has high Ca2+ and actin-activated ATPase activity, is
associated with a fast shortening velocity. In contrast,

MHC-~,

which has lower ATPase

activity, is associated with slower shortening velocity. MHC-a is the predominant MHC
isoform expressed in the ventricular tissue of normal adult rodents and other small
mammals, whereas

MHC-~

is highly expressed in the fetal and neonatal heart (Brandl, et

al., 1986, Lompre et al., 1984) In humans and other large mammals, MHC-a is only
predominant shortly after birth, with

MHC-~

the isoform predominantly expressed during

both fetal and adult life (Lompre et al., 1981 and Chizzonite, et al., 1984.). The situation
differs in the atria where MHC-a is the predominant isoform throughout life in both small

r

fr'

.
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and large mammals (Swynghedauw, 1986, Lompre et al., 1984 and Chizzonite, et al., 1984).

In the adult rat, acute LV pressure overload leads to the re-induction of the fetal isoform
(MHC-~)

and suppression of the high ATPase MHC-a isoform (Chassagne and Schwartz,

1993, Imamura et al., 1991, Izumo et al., 1987, Schwartz et al., 1992). The "isoform
switch" from MHC-a to MHC-~ results in a slower rate of ATP cycling by myosin, which
in part accounts for the decrease in the velocity of fiber shortening observed in the pressureoverloaded rat heart.

However, this isoform switch cannot explain reduced contractile

function in humans and other large mammals with pressure-overload LVH, since MHC
isoenzyme switching does not occur (Hoffmann and Grisk, 1986, Mercadier et al., 1983).
Thus other mechanisms must also be responsible for the slowed contraction observed in
LVH and CHF. In large mammalian ventricles, [Ca2+]i transients are likely to be the only
determinant of Vmax· Therefore, the membrane protein components responsible for changes
in [Ca2+]i may be the main determinants of changes in Vmax that occur in pressure overload
LVH.

2. Myocyte [Ca2+]i Mishandling During LVH and CHF.

It is well established that contraction in cardiac muscle is initiated by an increase in
2

[Ca

+]i.

Ca2+ enters the cell during the action potential via sarcolemmal Ca2+ channels (and

possibly also via Na/Ca exchange). Some of this Ca2+ contributes to direct activation of the
myofilaments, but Ca2+ influx also triggers the release of Ca2+ from an SR storage pool via a
process referred to as Ca-induced Ca release. The released and activator Ca2+ then binds to
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a comp

onent of the contractile apparatus (troponin C) which initiates actin-myosin cross2

bridge formation and muscle contraction. For relaxation to occur, Ca + must be removed
2

from the cytoplasm, allowing Ca + to dissociate from the myofilaments. There are several
2

systems in the cardiac muscle cell which contribute to [Ca +]i decline during cardiac
relaxation: (1) Ca2+can be transported back into the SR by the SR Ca ATPase; (2) Ca2+ can
be transported across the sarcolemma, either in exchange for Na+ (i.e. via the activity of the

Na-Ca exchanger), or by the activity of the sarcolemmal Ca-ATPase; or (3) Ca2+ can be
sequestered within mitochondria (Figure 1) (See Bers, 1991 for detailed review). The SR
ca ATPase and Na-Ca exchanger are by far the most dominant mechanisms, and the
relative contributions of these systems varies in different cardiac muscle preparations
(Hove-Madsen and Bers, 1993, Bassani et al., 1994 a). In adult rat LV myocytes, the
relative contribution of the various processes to [Ca2+]i decline were estimated as: SR 87%,
mitochondria 1.7%, Na-Ca exchanger 8.7%, sarcolemmal Ca-ATPase 2.6% (Negretti et al.,
1993). Because [Ca2+]i plays a central role in the process of cardiac excitation-contraction
coupling, [Ca2+]i mishandling may provide the basis for both systolic and diastolic
dysfunction in pressure overload. Morgan's group has shown that the prolonged isometric
contraction of cardiac tissue from animals with cardiac hypertrophy and humans with CHF
correlates with a similar prolongation of the calcium transient (Bentivegna et al., 1991,
Gwathmey et al., 1987, Gwathmey and Morgan, 1985, Bing et al., 1991). For instance, the
prolonged relaxation-phase of the isometric twitch observed in ferret right ventricular
pressure overload hypertrophy was associated with a markedly slowed decay of [Ca2+]i, as
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detected with aequorin (Gwathmey and Morgan, 1985). Prolonged [Ca +]i decline appears
to predominantly reflect the inability of the SR to sequester Ca during diastole. Although
slowed [Ca2+]i sequestration contributes to diastolic relaxation abnormalities, it is probably
not the only factor responsible for slowed relaxation.

A component of the impaired
2

diastolic relaxation seen in pressure overload hypertrophy is both energy and Ca

+

independent, and most likely reflects altered cross-bridge cycling rates and/or changes at the
level of the myofilaments (Gwathmey and Morgan, 1993). Furthermore, studies using
isolated myocytes from pressure overloaded, hypertrophied hearts have suggested that
changes in diastolic relaxation may be due to slowed resequestration of Ca2+, whereas the
decreased force generation of these preparations can largely be attributed to a decrease in
myofilament Ca2+ responsiveness (Wang et al., 1994, Bailey and Houser, 1992, Moore et
al., 1991).
In summary, [Ca2+]i during relaxation is primarily controlled by Ca2+ uptake by the SR.

The rate of sequestration (and perhaps the rate of release of Ca2+ by SR) is impaired in the
hypertrophied heart. Clearly, a potential cause for slowed relaxation may be related to the
activity of the enzyme largely responsible for SR calcium re-uptake during diastole, namely
the SR Ca 2+ ATPase.
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3. Changes In The Cardiac Extracellular Matrix (ECM) May Contribute To
Myocardial Functional Abnormalities In LVH And CHF.
Another characteristic of myocardial tissue from pressure overloaded hearts is changes
in compliance. The major determinant of ventricular tissue stiffness is the structure and
concentration of extracellular matrix collagens. The myocardium may be differentiated into
compartments occupied by cardiac myocytes and the interstitial space between these cells.
The interstitial space is composed of nonmuscle cells (i.e. cardiac fibroblasts and
endothelial cells) and a highly organized collagen network comprising the cardiac
extracellular matrix (ECM). The ECM serves to coordinate contractile force generated by
cardiac myocytes and contributes to the passive stretch characteristics of the ventricles.
Furthermore, muscle contraction is believed to compress elements of the cardiac ECM;
subsequent expansion of the matrix in diastole has been suggested to provide energy for
active re-lengthening of cardiac myocytes (Robinson et al., 1986). Thus deformation of the
ECM may help restore ventricular myocytes to precontraction length (Robinson et al., 1986,
Fouad et al., 1986). This expansion phase is thought to create suction that pulls blood into
the ventricles from the atria during the rapid filling phase of the cardiac cycle. The main
ECM proteins are collagen and fibronectin which are synthesized by nonmuscle cells
(Ahumada et al., 1981, 1984) and larninin which is synthesized by myocytes (Lungdren et
al., 1988). Type I and Type III collagens are the major collagenous proteins secreted by
cardiac fibroblasts. They form fibrils which comprise the elaborate weave and strut lattice
that surrounds individual cardiac myocytes and capillaries.

A substantial increase in
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collagen volume fraction has been observed in humans with aortic stenosis (Hess et al.,
1981, Schwarz, et al., 1978, Schaper and Schaper, 1983) and hypertension (Pearlman , et

al., 1982).

Similar changes have been observed in hypertensive, nonhuman primates

(Weber et al., 1988) and smaller mammals with experimental or genetic hypertension (Bing
et al., 1971, Thiedemann et al., 1983, Pfeffer and Pfeffer, 1985, Bartosova et al., 1969).
This accumulation of collagen was noted to be either diffusely distributed throughout the
myocardium or confined to the subendocardium, or both, and has been implicated as the
cause for the impaired diastolic stiffness (Hess et al., 1981) and pump capacity (Pfeffer and
Pfeffer, 1985) of the intact ventricle. Fibrillar collagens contain a unique amino acid (4hydroxyproline, or Hpro). Quantitative analysis of Hpro in acid hydrolysates of myocardial
tissue has been frequently used to assess fibrillar collagen content.

A strong positive

relationship between cardiac Hpro concentration and resting tension has well-documented
(Thiedemann, 1983, Willians, 1982). In addition, Bing et al (1971) noted that the velocity
of shortening of hypertrophied left ventricular columnar cavneae muscles (obtained after
constriction of the aortic arch) was reduced, and inversely related to the Hpro concentration
of the endomyocardium. A study by Jalil et al (1988) showed that the increase in passive
stiffness of the hypertrophied myocardium appears to be related to interstitial fibrosis. These
findings indicate that increases in collagen content and remodeling of the cardiac
interstitium are major determinants of increased myocardial stiffness and therefore, may
also play a very important role in diastolic dysfunction during pressure overload LVH and

CHF.
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D. SR Ca ATPase AND SERCA2 GENE IN HEART

In cardiac muscle, the SR plays a central role in the contraction-relaxation cycle by
2

virtue of its ability to regulate [Ca +]i. Ca2+ release from the SR increases [Ca2+]i (to a
maximal systolic concentration of 10-5M), thus inducing contraction, whereas Ca2+ uptake
by the SR reduces [Ca2+]i (to a minimum concentration of 10-7M during diastole), thus
causing muscle relaxation.

Cardiac pump function is thus tightly controlled by the

regulated release and removal of Ca2+ by the SR. In view of this key role in excitationcontraction coupling, alterations in SR function would be expected to significantly affect
cardiac performance. One of the most important myocyte proteins responsible for E-C
coupling is the SR Ca2+ ATPase. The SR Ca2+ ATPase is a 110 kDa integral membrane
protein that functions to transport Ca2+ from the cytoplasm into the SR lumen against its
electrochemical gradient, requiring the consumption of metabolic energy in the form of
ATP. The Ca pump also serves to "load" the SR and, in part, determines the amount of
Ca2+ that is available for release from the SR to activate myofilaments during subsequent
contractions.

1. SERCA2 Gene and SERCA Gene Family
Interest in the role of SR Ca2+ ATPase activity in normal muscle function has led to
considerable research into the structure and function of this enzyme and its gene. The
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cardiac SR Ca ATPase is an El-E2 type of trans-membrane protein, and belongs to a
multigene family (SERCA) which consists of five distinct isoforms encoded by three genes
(SERCAl, SERCA2 and SERCA3). The SERCAl gene is expressed exclusively in fast
skeletal muscle and encodes two alternatively spliced transcripts which differ in their
COOH termini. The SERCAl isoforms are developmentally regulated: adult skeletal
muscle expresses the SERCAla isoform, whereas neonatal skeletal muscle expresses the
SERCAlb type (Brandl et al., 1986). The SERCA2 gene product is alternatively spliced at
the 3' end producing SERCA2a which is present in the SR of cardiac and slow-twitch
skeletal muscle (Nagai et al. 1989, Lompre et al., 1989, Van Den Bosch et al., 1994), and
SERCA2b, which is expressed in the endoplasmic reticulum of smooth muscle and nonmuscle tissues in rat, rabbit and human (de la Bastie et al., 1988, Lytton et al., 1988, 1989,
Burk et al., 1989). The SERCA2b isoform is identical to the SERCA2a isoform except for
the replacement of the COOR-terminal four amino acids with an extended sequence of 49
amino acids. The functional differences between SERCA2a and SERCA2b can be ascribed
to the presence of the last 12 amino acids in SERCA2b (Verboomen et al., 1994). Since the
SR Ca ATPase in fast skeletal muscle (SERCAl) and cardiac muscle (SERCA2a) are
encoded by two different genes which share 84 % amino acid sequence identity
(MacLennan et al., 1985), the different properties of the two gene products may in part
account for the different relaxation properties of the corresponding muscle types (Lytton et
al., 1992, Wu et al., 1994). A third gene in the SERCA family (SERCA3) is also present in
both muscle and non-muscle tissue (Burk et al., 1989).
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2. Regulation of SERCA2 Gene Expression in The Heart.

a) Regulation of cardiac SERCA2 gene expression during ontogenesis and aging.
Myocardial function changes during ontogenic development (Hoerter and Lecarpentier,
1984, Hoerter et al., 1981, Chemla et al., 1986) and aging (Capasso et al., 1983, Froehlich et
al., 1978, Tate et al., 1990, Lakatta et al., 1987). Some of the developmental and ageassociated changes in the mechanical properties of the heart have been hypothesized to
result from differences in SR properties. In support of this hypothesis, several studies that
have compared SR properties in aged and adult rats have reported a decreased rate of Ca2+
uptake and a decreased Ca2+ ATPase activity with age (Froehlich et al., 1978, Tate et al.,
1990, Narayanan, 1987). In addition, the sensitivity to Ca2+ uptake does not vary with age,
whereas Ca2+

uptake and Ca2+-ATPase activity are lower in fetal than in adult SR

(Nakanishi and Jarmakani, 1984, Nayler and Fassold, 1977, Mahony and Jones, 1986, Pegg
and Nichalak, 1987, Komuro et al., 1989). More recent studies have demonstrated that
myocardial SERCA2a mRNA and protein levels increase dramatically during late fetal and
early neonatal life, and they achieve a stable, high level of expression during adulthood in
rat, rabbit and sheep (Arai et al., 1992, Lompre, 1991, Fisher et al., 1992, Antoon et al.,
1995, Mnger et al 1994, Mahony et al., 1986). These levels only decrease substantially
during late senescence (Besse et al., 1993, Maciel et al., 1990, Taffet and Tate, 1993), and
during pathological states such as hypothyroidism and severe pressure overload (for a
detailed review see below). The expression of the SERCA2a isoform is regulated in a cell-
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specific manner.

However, the expression of SERCA2b is neither tissue-specific nor

developmentally regulated. A very stable, low level of the SERCA2b gene is expressed in
the heart throughout life and during pathological states (Anger et al., 1994, Van Den Bosch
et al., 1994, Verboomen et al., 1994).

Thus, unlike the situation with many of the

contractile protein genes, changes in cardiac SERCA2 gene expression during pathological
states is not the result of isoform switching (Arai et al., 1992, de la Bastie et al., 1990, Nagai
et al., 1989).
b ). Regulation of SERCA2 mRNA and SR Ca ATPase expression during pressure
overload hypertrophy and heart failure. Alterations in SR Ca uptake have been extensively

investigated in hemodynarnic overload. A growing body of evidence suggests that Ca2+
uptake and SR Ca2+ ATPase activity are depressed in hemodynarnically overloaded,
hypertrophied hearts (Ito et al., 1974, Komuro et al., 1989, de la Bastie et al 1990, Levtsky
et al., 1991). Most studies have shown that the functional changes in SR Ca2+ uptake are
actually caused by a decrease in the amount of SR Ca2+ ATPase protein (Komuro et al.,
1989, de la Bastie et al., 1990, Levtsky et al., 1991 and Matsui et al., 1995). Others have
questioned this finding. For instance, Cory et al (1994) found that reduced in SR Ca2+
ATPase activity (as measured by Ca uptake by isolated SR vesicles) was not caused by a
decrease in the number of Ca2+ pumps, which was observed to be increased by 64% 3
weeks after coarctation of the abdominal aorta in guinea pigs. More recently, molecular
studies have demonstrated that SERCA2 mRNA levels are quantitatively decreased in nonfailing pressure overloaded hypertrophy models (Komuro et. al., 1989, Nagai et. al., 1989).
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Therefore, it has been proposed that reduced SERCA2 gene expression may play an
2

important role in the alterations in [Ca +]i handling and abnormal myocardial relaxation
observed in CHF. In support of this hypothesis, several groups have demonstrated that
SERCA2 mRNA and protein levels were markedly decreased in LV tissue of experimental
animals and humans with CHF (Arai et al., 1993, Hasefuss et al., 1994, Mercadier et al.,
1990, Studer et al., 1994). In contrast, Movsesian et al (1994) found that SR Ca2+ ATPase
protein content was not diminished in ventricular tissue from patients with idiopathic
dilated cardiomyopathy undergoing cardiac transplantation.

These results indicate that

down-regulation of SR Ca2+ ATPase may not be a part of the molecular pathophysiology of
all forms of end-stage human heart failure. Thus, the role of SR function in human heart
failure warrants further investigation.
The following issues must be considered when studying SR function in hypertrophied
and failing hearts. First, it should be noted that alterations in steady state mRNA levels
encoding SERCA2 do not always correlate with changes in SR Ca2+ uptake. There is
evidence to show that the reduction in SR Ca2+ ATPase protein concentrations is less
profound than the decrease in SERCA2 mRNA levels (Komuro et al., 1989, Matsui et al.,
1995). The other important issue is that alterations in SR function seem to depend on the
duration and severity, as well as the type of the hemodynamic overload produced (Table 2).
Increased SR Ca2+ uptake activity (Cuneo and Genda, 1988) or unaltered SERCA2 mRNA
levels. (Boluyt et al., 1994) have been reported in SHR rats with mild and severe LVH.
Enhanced SR Ca2+ uptake has also been documented in mild pressure overload hypertrophy
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(Limas et al., 1980 and Dhalla et al., 1984). Working with pressure-overloaded rats, de la
Bastie et al ( 1990) reported that SERCA2a rnRNA and protein levels were not reduced in
rnild hypertrophy (LV weight/body weight <2.6 g/kg), but were significantly decreased in
severe LVH (LV weight/body weight >2.6 g/kg) one month after abdominal AoC.
2

However, in both groups, SR Ca + ATPase activity was depressed irrespective of the degree
of LVH In contrast, Feldman et al ( 1993) demonstrated that the degree of hypertrophy did
not predict the degree of SERCA2 rnRNA down-regulation. SERCA2 rnRNA levels were
found to be decreased only in animals with clinical signs of CHF and diminished LV
systolic function (Table 2). The degree of SERCA2 rnRNA down-regulation may also be
related to the age of the animals in which pressure overload is initially induced. Takahashi
et. al (1992) showed that 5 days after ascending AoC, SERCA2 rnRNA levels were severely
reduced (by 69%) in 18 month-old (aged) rats, but not in 9-month old adult animals. In
addition to the above mentioned complications involved in the studies of the regulation of
SERCA2 gene expression during LVH and CHF, there is still no evidence to show a direct
link between down-regulation of SERCA2 gene expression and impaired diastolic function
in LVH and heart failure. Therefore, in order to prove that decreased SR Ca2+ ATPase
activity accounts for the defect in Ca handling and slowed diastolic relaxation observed in
both human and experimental heart failure, a thorough investigation of functional changes
in SR Ca2+ uptake, alterations in SR Ca ATPase protein and rnRNA levels, and correlation
of the above changes with changes in hemodynamic indices during LVH progression must
be conducted.
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The studies reviewed here also do not clarify whether down-regulation of SERCA2 gene
expression contributes to the transition from "compensated" hypertrophy to CHF. To date,
there are no reliable "molecular markers" that can identify the transition from compensated
hypertrophy to CHF, or guide therapy for this disorder. There is still a lack of convincing
2

evidence to link the defect in SR Ca + uptake with hemodynamic abnormalities during the
transition to CHF. Only very recently, Hasenfuss et al. (1994), reported that protein levels
of SR Caz+ ATPase were reduced in failing human myocardium. SR Ca2+ ATPase protein
2

levels were closely related to SR Ca + uptake and more importantly, were also correlated to
the force-frequency behavior of human myocardium. Therefore, their results suggest SR
Caz+ ATPase protein levels indeed determine the systolic contractile reserve with respect to
frequency potentiation of contractile force in the human heart.

Feldman et al. (1993)

showed that a reduction in SERCA2 mRNA levels was linked to the progression of clinical
and hemodynamic indices of LV systolic dysfunction in a rat model of LV pressure
overload (thoracic AoC).

However, in vivo hemodynamic measurements were not

performed (due to the position of the constricting aortic band) so that the question of
causality was not adequately addressed.

Furthermore, pressure overload produced by

abdominal AoC is an experimental model of L VH that seems to more closely mimic human
chronic pressure-overload. This dissertation study will provide a comprehensive study of in
vivo hemodynamics and changes in SERCA2 and contractile protein gene expression over

time to determine whether alterations in SR Ca2+ pump activity contributes to the transition
from LVH to CHF in the rat abdominal AoC model.
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It is well known that the function of the cardiac SR Caz+ pump is modulated by a

phosphoprotein, namely phospholamban, with a molecular weight of 25 kDa (Kirchberger
et al., 1974)

Phosphorylation of phospholamban by cAMP-dependent protein kinase

significantly increases the rate of Caz+ uptake (Kranias et al., 1985). There are no isoforms
of phospholamban, and the same protein is expressed in cardiac and slow-twitch skeletal
muscle (Fujii et al., 1987). It has been reported that phospholamban mRNA levels are
down-regulated in pressure overload hypertrophy and CHF in both animal models (Nagai, et
al., 1989, Matsui, et al., 1995) and in humans (Feldman et al., 1991 and Arai et al., 1993).
Interestingly, phospholamban mRNA shows a decrease parallel to that of SERCA2 in
failing hearts, indicating that the expression of these two genes may be coordinately
regulated.
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TABLE2
Alterations in SR Ca2+ uptake in pressure overload hypertrophy.

Thoracic AoC
;;t (Takahashi et al. 1992)

i

rat (Feldman et al., 1993)

I

!

I H adult, .J, old
I H8,20 wk, non-HF

Abd~·~~~T·A:~C'·-···············---·-·--·····+----·--·······-······· . . . . . . . . ._ ..J_________. . . . . . . . . . . _J
rat (Komuro et al., 1989)

I1

I1

rat (de la Bastie et al., 1990) j

.t
t

rat (Levitsky et al., 1991)

1

pig (Dhalla et al., 1984)

ii l4wkJ8wk

rat (Limas et al., 1980)

11

I

I

.J,

i

.J,

..........

I1
mild L VH

I 1 severe LVH

.J,

I

H

.J, 2 Q..~k, l!i:. .-

I Hrnild L VH

!1severe LVH
I .J,

I
I

guinea pig (Cory, 1994)

II

PA banding
rabbit (Matsui, 1995)

i .J,

i

l

l

.J,

SHR
Cuneo & Genda, 1988
Boluyt et al., 1994

AoC, aortic coarctation; E-P indicates phosphorylated intermediate of the Ca2+-ATPase;
PA, pulmonary artery; SHR, spontaneously hypertensive rat; i, increase; ~. same as
control; J,, decrease. HF, heart failure.

,.
.

.
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c.)

Cellular and molecular mechanisms involved in regulating cardiac SERCA2 gene

ion To date, little is known about the cellular and molecular mechanisms involved
expresS ·
in the regulation of SERCA2 gene expression. Thyroid hormone has been found to regulate
the SERCA2 gene in cardiac myocytes both in vivo and in vitro. Exogenous administration
of thyroid hormone increases cardiac SERCA2 mRNA and protein levels in vivo and in cell
culture (Arai et al., 1991, Nagai et al., 1989, Rohrer et al 1988, 1991, Ojamaa et al., 1992,
brain-Herzberg et al., 1994), whereas experimentally produced hypothyroidism decreases
SERCA2 gene expression in vivo (Arai et al., 1991, Rohrer et al., 1988). In addition,
fibroblast growth factors such as acidic and basic fibroblast growth factor (aFGF and bFGF)
and transforming growth factor type ~ (TGF-~) have been found to down-regulate SERCA2
mRNA levels in cultured neonatal rat ventricular myocytes (Parker et al 1990), although the
molecular mechanisms responsible for this down-regulation are not known.
Since the SERCA2 gene is tissue-specific, developmentally regulated, and responsive to
specific pathophysiological conditions of heart muscle, it is an excellent model gene to
study the complexity of myocyte transcriptional control. Transcription is a primary control
point in the regulation of gene expression.

The transcriptional machinery integrates

regulatory information though the binding of trans-acting factors to cis-acting DNA
elements. These DNA elements are found both proximal and distal to the transcription
initiation site, and are involved in the activation or repression of transcription. Fisher et al
(1993) and Rohrer et al (1991) have characterized upstream regulatory sequences from the
transcriptional start site to -658 bp of rabbit SERCA2 gene and -559 bp of the rat SERCA2
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gene respectively, as regions producing high-level transcriptional activity in cardiac
myocytes. The 5' -flanking region of the SERCA2 gene is very G/C-rich. This region
contains several consensus sequences that are likely to be important sites of interaction with
nuclear proteins involved in regulating gene transcription. These include a "TATA box"
like 5'-GATAAA-'3 sequence, a "CAAT box" (5'-GCCAAT-3') sequence, and 2-3 SPl
consensus sequences (5' -GGCGGG-3 ') (Zarin-Herzberg et al., 1990, Sukovich, 1993, and
Rohrer et al., 1991). These bind, respectively, the transcription factor II complex, the CTF
family of transcription factors, and the zinc finger protein SPl, which have been previously
shown to promote transcription of a variety of eukaryotic muscle and nonmuscle genes
(Faisset and Meyer, 1992). A similar 17 bp upstream promoter element (UPE) with 88%
homology in rabbit and rat was also identified in the proximal promoter region of SERCA2
gene (Sukovich,1993, and Rohrer et al., 1991).

Gel mobility shift and Southwestern

analyses using the 17 bp UPE have revealed a specific DNA binding complex referred to as
Ca2+ ATPase promoter factor-l(CaPFl). The binding factor has an approximate Mr of 43
kDa and is a novel DNA-binding protein which plays a role in SERCA2 gene expression in
skeletal muscle (Sukovich,1993).

One to three thyroid hormone-responsive elements

(TREs) have also been identified within the 5' upstream regulatory sequences of the rat and
rabbit SERCA2 genes respectively (Rohrer, 1991, Hartong et al., 1994 and Zarin-Herzberg
et al., 1990,1994). These sequences bind nuclear thyroid hormone receptors and up-regulate
SERCA2 transcription in response to exogenous T3.

Although it appears that other

humoral signals in addition to thyroid hormones, and mechanical factors may be involved in
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SERCA2 gene regulation, their effects on SERCA2 gene transcription, rnRNA processing
and stability, and translation are unknown.

E. CARDIAC MYOCYTE HYPERTROPHY --IN VITRO MODEL

The reduced SERCA2 rnRNA levels observed in pressure-overloaded, hypertrophied
hearts occurs in the presence of normal circulating levels of thyroid hormones, indicating
that other factors (including a direct effect of mechanical load) may regulate SERCA2 gene
expression in vivo. Obviously, it is difficult to study the role of mechanical factors in the
regulation of SERCA2 gene expression during pressure overload, and to identify second
messengers that may be involved in transducing mechanical signals from the cell surface to
the nucleus. One critical advance in the study of the mechanisms of cardiac myocyte
hypertrophy has been the development and characterization of primary cultures of neonatal
rat myocytes (Chien et al., 1991).

1. Induction of Cardiac Myocyte Hypertrophy in vitro

Mechanical and hormonal factors have often been proposed as the initial triggers
inducing the well-known qualitative changes in cardiac gene expression during pressure
overload LVH.

Pressure overload produces two different mechanical effects on the

myocardium: increased passive stretch and increased active tension development.

The

effects of both mechanical stimuli on induction of cardiac myocyte hypertrophy have been
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widely investigated using primary cultures of neonatal rat ventricular myocytes. It has been
documented that either spontaneous (McDermott et al., 1985, 1989a and 1989b, Samarel
and Engelmann, 1991 ), or electrically stimulated (McDonough and Glembotski, 1992,
Johnson et al., 1994) contractile activity, and passive stretch (Komuro et al., 1991,
Sadoshima et al., 1992) of cultured cells mimics many features of the pressure overloadinduced hypertrophic response in vivo. On the other hand, diverse and distinct hormonal
stimuli that may be important regulators of pressure overload hypertrophy in vivo have clear
growth-promoting effects in the in vitro system. A number of studies have demonstrated
that cardiac myocyte hypertrophy can be induced in cell culture by a.1-adrenergic agonists
(Simpson et al., 1991, Waspe et al., 1990), endothelin (Suzuki et al., 1990), angiotensin II
(Ang

m (Baker and Aceto,

1990, Sadoshima and Izumo, 1993 a and b), peptide growth

factors (e.g. transforming growth factor-p, fibroblast factors. Parker et al., 1990), serum
stimulation (Qi et al., 1994), and a-thrombin receptor activation (Glembotski et al., 1993).

2. Characteristics of Cardiac Myocyte Hypertrophy in vitro

Cardiac myocyte hypertrophy induced by mechanical and hormonal stimuli in vitro have
the following common features: (1) an increase in the size of myocytes accompanied by
accumulation of myocyte protein (as evidenced by increases in total protein content,
protein/DNA ratio and protein synthetic capacity); (2) the induction of IE response genes
such as cjos, c-jun, and Egr-1; (3) the re-expression of "fetal", late response genes such as
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ANf, MHC-~ and a-skeletal actin; and (4) the up-regulation of the constitutively expressed
contractile protein myosin light chain 2 (MLC-2) gene.

3. Mechanical Load Induced Cardiac Myocyte Hypertrophy.

In primary cultures of neonatal rat cardiac myocytes, spontaneous and electrically

stimulated contractile activity produces myocyte hypertrophic growth, as measured by total
protein and RNA accumulation (Allo et al., 1992, McDermott et al., 1989, Johnson et al.,
1994 and Samarel and Engelmann, 1991). An increased protein synthetic capacity, as
reflected by a net increase in rRNA content, is the primary translational mechanism by
which the rate of protein synthesis is accelerated in spontaneously contracting or electrically
stimulated cells (McDermott, 1991, Johnson et al., 1994). In terms of specific proteins,
changes in the synthesis rates of actin and myosin have been shown to occur in contracting
cells, either by transcriptional mechanisms involving selective changes in mRNA levels or
by a post transcriptional process (Samarel and Engelmann, 1991 and McDermott et al.,
1987). The present study also shows that contractile arrest up-regulates SERCA2 mRNA
levels (Bassani et al., 1994). However, the signal transduction pathways involved in the
gene regulation of contraction-induced cardiac myocyte growth is still largely unknown.
Our previous studies (Samarel, Qi et al., 1994) have suggested that up-regulation of MHC-~
may involve PKC activation. In contrast, McDonough and Glembotski (1992, 1994) found
that electrically stimulated induction of ANF and MLC-2 gene expression was dependent
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primarily on [Ca +]i and Ca +/calmodulin-dependent protein kinase II (CaMK) and
independent of PKC.
The other widely used model to study how mechanical load induces the hypertrophic
phenotype is to passively stretch cardiac myocytes that are adherent to an elastic membrane.
Several studies (Komuro et al., 1990,1991, Yazaki and Komuro, 1992, Sadoshima et al.,
1992) have demonstrated that stretching neonatal rat cardiac myocytes attached to laminincoated silastic membranes induced myocyte hypertrophy as evidenced by an increase in
protein synthesis and content without an increase in DNA synthesis. The phenotype of
stretched cardiac myocytes in vitro highly resembles that of hemodynarnic overload induced
hypertrophy in vivo. Specifically, stretch causes a rapid and transient induction of a variety
of IE genes (e.g. c-fos, c-jun, c-myc, JE and Egr-1), followed by activation of fetal genes,
such as a-skeletal actin, MHC-p, and ANF which are all late response genes characteristic
of rat ventricular hemodynarnic overload in vivo (Komuro et al., 1990,1991, and Sadoshima
et al., 1992). Stretch-induced c-fos gene expression is regulated at the transcriptional level,
and the "stretch-responsive element" within the 5' flanking region of the c-fos gene is
identical to the previously described serum-response element (SRE) which binds serum
response factor (SRF), a transcription factor that regulates the transcription rate of a variety
of muscle and nonmuscle genes (Komuro et al., 1991, and Sadoshima et al., 1992).
However, it appears that stretch-induced increases in MHC-P and ANF mRNAs may not be
regulated at the transcriptional level (Sadoshima et al., 1992). These above mentioned
effects could be prevented by pre-treatment of cells with the PKC inhibitors H7 and
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staurosporine, or by prior down-regulation of PKC by chronic exposure to phorbol esters.
Myocyte stretching results in small but significant increases in the levels of inositol
phosphates, 1,2,-diacylglycerol (DAG) and PKC activity, suggesting that PKC is activated
by mechanical stress (Komuro et al., 1991, Yazaki et al., 1993, Sadoshima and Izumo, 1993
and Komuro and Yazaki, 1994). Myocyte stretching was also shown to activate mitogenactivated protein (MAP) kinase (Yamazaki et al., 1993 and Sadoshima and lzumo, 1993).
When PKC was depleted by preincubating myocytes with phorbol ester or its activity was
blocked by the PKC inhibitor staurosporine, stretch-induced MAP kinase activity was
decreased by 60-70%. These results suggest that the stretch-induced increases in MAP
kinase activity occurs through both PKC-dependent and independent pathways.
Subsequently, Sadoshima and lzumo (1993) demonstrated that myocyte stretching causes
rapid activation of multiple second messenger systems, which may in tum initiate a cascade
of pleiotropic responses.

Unfortunately, little is known as to how muscle cells sense

mechanical load and transduce it into intracellular signals of gene regulation (Sadoshima et
al., 1992).

4. Hormone Induced Myocyte Hypertrophy.

Angiotensin II (Ang

macts as a direct growth factor for cardiac myocytes.

It causes a

rapid induction of IE genes such as c-fos, c-jun, and Egr-1 and hypertrophy in cardiac
myocytes (Baker and Aceto, 1990, Sadoshima and Izumo, 1993b & c). Ang II also induces
the expression of "fetal" genes such as ANF, a-skeletal actin and up-regulates the
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expression of growth factor genes, such as TGF-~ and angiotensinogen (Sadoshima and
Jzumo, 1993b). Sadoshima and lzumo ( 1993c) also found that Ang II activated multiple
phospholipid-derived second-messenger systems. PLC and PKC seem essential for Ang IIinduced c-fos gene expression, whereas Ca2+ may play a permissive role. The "Ang II
response element" of the cjos promoter also maps to the PKC-dependent portion of the
serum response element.
Chronic exposure to an a 1-adrenergic agonist causes hypertrophic growth of cultured
neonatal rat ventricular myocytes. This hypertrophic response is accompanied by activation
of PKC activity, which can be inhibited by incubating myocytes with the PKC inhibitor
staurosporine (Henrich and Simpson, 1988, Allo et al., 1992). These results indicate that
PKC activation may play a very important role in a 1-adrenergic activation of cardiac
myocyte hypertrophy.

F. ROLE OF PKC ACTIVATION IN CARDIAC MYOCYTE HYPERTROPHY
AND GENE EXPRESSION

As is apparent from the information presented above, protein kinase C activation may be
centrally important in signaling the hypertrophic phenotype in response to a diverse number
of exogenous stimuli.

Therefore, a brief overview of protein kinase C structure and

function in cardiac tissue is now presented.
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1. PKC Isoenzymes in Heart.
a). PKC isoforms. PKC is a family of closely related serine-threonine protein kinases

that can be classified into conventional PKCs (cPKC), new PKCs (nPKC) and atypical
PKCs (aPKC).

As shown on Table 3, there are 10 identified subspecies of PKC in

mammalian tissues (Asaoka et al., 1992). The cPKCs are characterized enzymatically by
their requirement for Ca2+, phospholipids, and DAG or phorbol ester for activation. This
reflects the presence of four conserved domains.

The Cl region 1s the putative

phospholipid-and DAG/phorbol ester-binding domain, the C2 region is the putative
calcium-binding domain, and the C3 and C4 regions constitute the kinase domain. The
nPKCs are structurally related to the cPKCs. However, they lack the C2 domain and do not
require Ca2+ for maximal activation. PKC I; also differs from other members of the PKC
gene family in that it contains only one cysteine-rich zinc finger like motif in the Cl
domain.

As a result, neither Ca2+ nor DAG/phorbol ester activates this PKC isoform

(Figure. 2) (Nishizuka, 1992).
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TABLE3
PKC subspecies in mammalian tissues

nPKC

aPKC

76,790

c a2+ '

~II

76933

PS,

"{

78366

LysoPC

Brain only

b

77517

DAG, PS

Universal

E

83474

DAG,PS,FFA

Brain and other tissues

ll(L)

77972

?

Lung, skin, heart

e

81571

?

Skeletal muscle

t;

67740

PS,FFA

Universal

/..,

67200

?

Ovary,

DAG,

Some tissues

FFA, Many tissues

testis

and

others

a. The activators for each subspecies are determined with calf thymus Hl histone and
bovine myelin basic protein as model phosphate acceptors.
Abbreviations: DAG, diacylglycerol; PS, phosphatidylserine; FFA, cis-unsaturated fatty
acid; LysoPC, lysophosphatidylcholine.
Adapted from Asaoka, et al., 1992.
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Figure 2: Structure of PKC subspecies. C =constant. V =variable.
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b). Activation and down-regulation of different PKC isoenzymes in heart. Currently,
there is some controversy concerning which PKC isoforms are expressed in adult and
neonatal rat cardiac myocytes and which PKC isoenzymes mediate cardiac myocyte
functions. Bogoyevitch et al (1993) reported that only E-PKC was expressed in adult rat
cardiac myocytes. However, RT-PCR, along with restriction enzyme mapping and DNA
sequencing revealed the presence of a-, 8-, E-, 8-and s-PKC isoforms in adult rat cardiac
myocytes and cultured neonatal ventricular myocytes (Kohout and Rogers, 1993). A recent
publication by Puceat et al (1994) using Western blot analysis reported that both neonatal
and adult rat cardiac myocytes express a-, 8-, E-, and s-PKC isoenzymes. Furthermore,
Rybin and Steinberg (1994) found different patterns of PKC isoenzyme expression in
neonatal (a-, 8-, E-, and s-PKC) and adult rat (8- and E-PKC) cardiac myocytes. Church et
al (1993) demonstrated that neonatal cardiac myocytes contain a-,~-, 8-, and s-PKC but not
E-PKC isoenzymes by Western blotting analysis. Mochely-Rosen and coworkers (MochelyRosen et al., 1990, Disatnik et al.,

1994) showed by irnrnunofluorescence studies the

presence of a-, ~I-, ~II-, 8-, E- and s-PKC isoenzymes in neonatal cardiac myocytes, each of
which is translocated to distinct subcellular sites after stimulation by norepinephrine or
PMA. Differences in translocation site of individual isoenzymes- and, potentially, their
phosphorylation of different substrates localized at these sites may explain the diverse
biological effects of PKC. A recent study (Gu and Bishop, 1994) found that a-, ~I-, ~II-, E-,
and s-PKC isoenzymes were present in both soluble and particulate fractions, whereas PKC
8 was only present in the nuclear-cytoskeleton of the particulate fraction of normal adult rat
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heart tissue. PKC-~I, ~II and PKC-E were increased in response to pressure overload (Gu
and Bishop, 1994). These results further suggest that PKC plays an important role in the
regulation of cardiac myocyte growth and function in the development of hypertrophy and
that individual isoenzymes may perform different functions in response to pathological
conditions.
There have also been several studies of PKC isoenzyme translocation and downregulation in cardiac myocytes (Disatnik et al., 1994, Bogoyevitch et al., 1993 and 1994,
Puceat et al., 1994, Rybin and Steinberg et al., 1994 and Church et al., 1993). Puceat et al
(1994) found that a 1-adrenergic or P 2 purinergic receptor activation in neonatal cardiac
myocytes elevated membrane-associated immunoreactivity of 8- and E-PKC. In addition,
they found that a short treatment with PMA (100 mM) caused redistribution of a-, 8-, and EPKC isoenzymes in these cells. Longer PMA treatment caused substantial down-regulation
of the a- and 8-PKC but not the E-PKC isoenzyme. These authors also found a PKCmediated increase in myristoylated alanine-rich PKC substrate (MARCKS) phosphorylation
and c-fos mRNA accumulation. The former but not the latter function was correlated with
the persistence of E-PKC after PKC activation and down-regulation. Johnson and MochlyRosen( 1995) used many different antisera to demonstrate that PMA has differential effects
on the distribution and levels of a, ~I, ~II, 8, E and s-PKC isoenzymes in cultured neonatal
rat ventricular myocytes. In agreement with Puceat et al., their study found a-PKC to be the
most sensitive and E-PKC to be the least sensitive PKC isoenzyme to PMA-induced downregulation. However, in contrast to Puceat et al., they found the 8-PKC isoenzyme was
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similarly resistant to PMA induced down-regulation as E-PKC. The above mentioned study
also suggested that the E-PKC isoenzyme may modulate the contraction rate of neonatal
cardiac myocytes.

2. PKC Activity in Cardiac Hypertrophy in vivo
Several types of cardiac hypertrophy have been associated with changes in PKC activity
in cardiac tissue. Both cytosolic and particulate PKC activities were to be found markedly
increased in cardiac tissue of hypertrophic myopathic hamsters (Chambers and Eilon, 1988,
Chi et al., 1993). In the rat with thoracic AoC, cytosolic and membrane associated PKC
activities were significantly elevated. The increased PKC activity may be involved in the
increased

phosphorylation

of cardiac

MLC

protein

in

myocardial

hypertrophy

(Kwiatkowsha-Patzer and Domanska-Janik, 1991). It has been reported that particulate
PKC activity was enhanced in stroke-prone spontaneously hypertensive rat heart cells in
response to norepinephrine stimulation (Kawaguchi et al., 1993).

A recent study

demonstrated that PKC activity and content were increased during development of pressure
overload induced LVH. Furthermore, the increased PKC isoenzymes were mainly limited to
PKC1,2 and PKC-E, and the increases were present mainly in the membrane and nuclearcytoskeletal fractions (Gu and Bishop, 1994).
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3. Role of PKC Activation in Cardiac Myocyte Hypertrophy in vitro
As mentioned previously, PKC activation has been associated with mechanically
(spontaneous contraction or passive stretch) and hormonally (Ang II and a1-adrenergic
activation) induced cardiac myocyte hypertrophy in vitro. PKC activation by PMA in cell
culture also reproduces many of the changes in gene expression that occur in the pressure
overloaded heart in vivo, such as an increase in protein synthetic rate (Fuller and Sugden,
1989), induction of IE gene expression (Dunnmon et al., 1990) and up-regulation of MLC-2
(Shubeitha et al., 1992), ANF (Shubeitha et al., 1992), a-skeletal actin (Komuro et al.,
1991) and MHC-P (Kariya et al., 1991, Samarel and Engelmann, 1991). Co-transfection of
MLC2 and MHC-P promoter-reporter gene constructs with constitutively active, mutant
forms of PKC (Shubeita et al., 199, Kariya et al., 1991, respectively), and nuclear run-on
assays of PMA-treated neonatal rat myocytes (Dunnmon et al., 1990) demonstrated that the
hypertrophic effects of PKC activation are in part regulated at the level of gene
transcription. However, phorbol esters may also stimulate rat myocyte protein synthesis at
the translational level by increasing protein synthetic efficiency (Fuller and Sugden, 1989)
and capacity as evidenced by an increase in total RNA and rRNA (Allo et al., 1991, 1992).
In contrast, inhibition of PKC activity by the protein kinase C inhibitor staurosporine in

contracting cells markedly decreased MHC-P mRNA levels (Qi et al., 1994, Samarel and
Engelmann, 1991).

Overall, these results suggest that PKC activation may play an

important role in many of the signal transduction pathways leading to cardiac myocyte
hypertrophy. However, very little is known about the role of PKC in the regulation of
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SERCA2 gene expression in these cell culture models. This will be specifically addressed
in this thesis.

G. ROLE OF [Ca2+]i IN CARDIAC MYOCYTE HYPERTROPHY.
Since changes in [Ca2+]i accompany alterations in the contractile state of the
myocardium and elevation of [Ca2+]i can activate several isoforms of PKC, it has long been
thought that alterations in [Ca2+]i might represent a logical stimulus for coupling changes in
contractility with alterations in cardiac metabolism and gene expression in response to
pressure overload (Kaibuchi et al., 1986, MacKinnon et al., 1988). Although no direct role
for the changes in [Ca2+]i during cardiac hypertrophy have yet to be described, inhibition of
spontaneous contractile activity by Ca channel blockers decreases the capacity for protein
synthesis, inhibits total myosin synthesis and accumulation, and markedly reduces MHC-B
gene expression in neonatal rat heart cells (Qi et al., 1994, Samarel and Engelmann, 1991).
In addition, the down-regulation of the SERCA2 gene can alter [Ca2+]i by slowing Ca re-

uptake by the SR.

2

It is possible that changes in [Ca +]i may regulate SERCA2 gene

expression via a negative feed-back loop. Therefore, the role that [Ca2+]i plays in regulating
SERCA2 gene expression will be specifically investigated in the present study.
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n.suMMARY.

Pressure overload LVH and CHF are often associated with impaired diastolic function.
2

[Ca2+]i during relaxation which is primarily controlled by Ca

+

uptake via the SR Ca2+

ATPase. It has been well documented that SR Ca2+ ATPase mRNA and protein levels as
well as SR Ca2+ uptake are decreased during pressure overload hypertrophy and CHF in
experimental animals and humans. Clearly, a potential cause for slowed relaxation may be
related to the activity of SR Ca2+ ATPase. However, there is still no evidence to show a
direct "cause and effect" relationship between the down-regulation of the SERCA2 gene
and impaired diastolic function during pressure overload hypertrophy and CHF. More
importantly, the studies reviewed here do not clarify whether down-regulation of SERCA2
gene expression contributes to the transition

fro~

"compensated" hypertrophy to CHF.

Therefore, this dissertation study will provide a comprehensive study of in vivo
hemodynamics and changes in and SERCA2 and compositional proteins (including myosin
isoenzymes and fibrillar collagens) during the progression of rat pressure overload LVH to
determine whether alterations in SR Ca2+ ATPase contributes to the transition form LVH to
CHF.
Although thyroid hormone is known to regulate the SERCA2 gene at the transcriptional
level, the cellular and molecular mechanisms responsible for the regulation of SERCA2
gene expression during pressure overload hypertrophy and CHF are still largely unknown.
Mechanical stimuli are known to play a very important role in the induction of LVH in the
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pressure overloaded heart. PKC and other kinases are likely to be involved in transducing
extracellular stimuli during pressure overload hypertrophy. Whether mechanical stimuli and
PKC activation are involved in the regulation of SERCA2 gene expression in pressure
overloaded and failing hearts are still unknown but will be thoroughly studied in this
dissertation work using primary cultures of neonatal rat ventricular myocytes.

CHAPTER III
MATERIALS AND METHODS

A. REAGENTS.

1. Materials and Culture Media for Cell Culture Experiments

Tissue culture plates were obtained from Costar (Cambrigde, MA). Swim's-S77, Ca2+Mg 2+ -free Hanks' balanced salt solution (HBSS), Antibiotic-Antimycotic Solution
(lOOx), Gentamycin, L-glutamine, Dulbecco's modified Eagle's medium nutrient mixture

F-12 Ham (DMEM/F12), Acid soluble collagen (Calf skin type I), actinomycin D (ActD), (±)-verapamil and 4a-phorbol were purchased from Sigma Chemical Co (St. Louis,
MO). Staurosporine and chelerythrine were obtained from LC Laboratories. (Woburn,
MA).

Collagenase (type CLSII) was obtained from Worthington Biochemical Corp.

(Freehold, NJ).

Fetal bovine serum was purchased from HyClone Laboratories,

Inc.(Logan, Utah). Lipofectamine and Optimem I medium were obtained from GIBCOBRL (Cleveland, OH).

All other reagents were of the highest grade commercially

available and were obtained from Sigma and Baxter SIP (McGaw Park, IL).
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PC-1 medium: PC-1 tissue culture medium was obtained from Hycor Biomedical
Inc.(Irvine, CA).

According to the manufacturer, PC-1 medium is formulated in a

specially modified DMEM/F12 base and contains a complete HEPES buffering system
with insulin (15 µg/ml), T3 (0.5 nM), fatty acids, and proprietary proteins (at a
concentration of less than 530 µg/ml). 500 ml of PC-1 medium was completed by adding
1 vial of PC-1 supplement, 5 ml of 2 mM L-glutamine, and 5 ml of AntibioticAntimycotic Solution (lOOx).

2. Reagents for Molecular Biology Assays.
Agarose was obtained from FMC BioProducts (Rockland, ME). Guanidine thiocyanate
was purchased from Fisher Biotech (Fair Lawn, NJ). 3-[N-Morpholino] propane sulfonic
acid (MOPS) was obtained from Sigma. 20 x SSC (3 M NaCl and 0.3 M Na Citrate, pH
7.0), salmon sperm DNA, 50% Dextran sulfate were purchased from 5 Prime-3 Prime Inc
(Boulder, CO). Restriction enzymes and Taq polymerase were obtained from Phamacia
Biotech (Piscataway, NJ). Competent E. Coli 5Ha (DH5a), T 4 polynucleotide kinase, T 4
DNA ligase, deionized formamide, Luria-Bertani (LB) medium, 123 bp and 1 kb DNA
ladders were obtained from GIBCO-BRL.

Multiprime DNA labeling system, (a-

32P)dCTP, (a- 35 S)dATP, and (y- 32P)ATP were purchased from Amersham. QIAGEN
plasmid purification kit was purchased from QIAGEN INC. (Chatsworth, CA). Human
glyceraldehyde 3-phosphate dehydrogenase (GAPDH, clone pHcGAP) cDNA was
obtained from American Type Culture Collection (Rockville, MD) and the rat SERCA2
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cDNA clone is a gift from Dr. Wolfgang Dillmann, (UCSD). 40-base oligonucleotide
probes specific for the 3' untranslated regions of the rat MHC-a and

MHC-~

genes were

obtained from Oncogene Science, Uniondale, NY. An oligonucleotide probe specific for
rat 18S rRNA (5'-ACGGTATCTG ATCGTCTTCG AACC-3') (Chan et al., 1984) was
kindly synthesized by Dr. Bassam Wakim (Loyola University Medical Center, Maywood,
IL.). Sequenase version 2.0 DNA sequencing kit was obtained from USB (Cleveland,
OH).

3. Reagents for Biochemical Assays
Rabbit anti-rat SERCA2 antiserum was a generous gift from Drs. Ronald Hartong and
Wolfgang Dillmann, UCSD.

Goat anti-rabbit IgG conjugated with horseradish

peroxidase was purchased from CAPPEL Inc (Durham, NC). Protein rainbow molecular
weight standards and enhanced Chemoluminescence kits were obtained from Amersham.

B. ADULT RAT ABDOMINAL AoC MODEL.

.

Male Sprague-Dawley rats (Harlan Industries, Indianapolis, IN) weighing 160-190 g
were randomly divided into sham and aortic banded groups. Animals were anesthetized
with an intramuscular injection of ketamine (70 mg/kg) and xylazine (2 mg/kg).

A

midline abdominal incision was used to expose the left renal vascular bundle and the
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abdominal aorta was dissected free to isolate a 2-cm segment.

Coarctation of the

abdominal aorta was produced using a tantalum hemoclip as previously described
(Eleftheriades et al., 1993). The applicator was modified to allow passage of a 25 g
needle through the hemoclip when completely closed. Sham operated animals underwent
anesthesia and dissection of the abdominal aorta without application of the suprarenal
band. The peritoneum was closed with 5-0 silk suture and the skin was closed with a 9
mm Autoclip applicator (Clay Adams, Parsippany, NJ). All animals received food and
water ad libitum. Sham and banded animals were investigated at 8 and 16 weeks after
surgery.

C. HEMODYNAMIC MEASUREMENTS IN VIVO.

Rats were anesthetized with ketamine-xylazine, body weight was recorded, and the
right carotid artery was exposed through a small cervical incision.

A 3-F

micromanometer-tipped catheter (MMI-Gaeltec, Hackensack, NJ) interfaced to a Gould
2400S Recorder (Gould Instrument Systems, Valley View, OH) was inserted into the
right carotid artery and advanced to the level of the aortic arch. After recording systolic,
diastolic and mean arterial pressures (SAP, DAP, and MAP, respectively), the catheter
was advanced across the aortic valve to obtain LV systolic and diastolic pressures.
Analog signals were simultaneously digitized (1,000 Hz) and stored on videotape for
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subsequent analysis of peak systolic LV pressure (LVP), L V end-diastolic pressure
(LVEDP), maximal +dP/dt (+dP/dtmax, defined as maximal rate of rise of the LVP),
maximal -dP/dt (-dP/dtmax, defined as maximal rate of fall of the LVP), contractility index
(Cl, defined as (+dP/dtmax)ILVP at peak +dP/dt), and the time constant for isovolurnic
relaxation ('t) using the PO-NE-MAH algorithm software package. 'twas computed using
the linear regression of dP/dt versus LVP during isovolurnic relaxation as described by
Martin et al. (1984). Animals were then administered an overdose of pentobarbital and
the heart was excised and quickly weighed. After further dissection, the left ventricle (LV
free wall + septum) was weighed, immediately frozen in liquid N2 and stored at -70 °C
for further analysis.
In some experiments, Ca2+ tolerant, LV myocytes were isolated from the hearts of
sham and 16 wk banded rats as previously described (Bassani et al., 1992). Freshly
isolated cells were pelleted by centrifugation, resuspended in 150 rnM NaCl, and
homogenized.

D. HYDROXYPROLINE ANALYSIS.

LV tissue (100-200 mg) was homogenized in 19 vol of 150 rnM NaCl. After removal
of an aliquot for analysis of total protein content by the Lowry method, a portion was
added to 2 vol of ethanol, and the precipitated proteins were hydrolyzed in 6N HCl
(110°C, 24 h). The hydrolysates were evaporated to dryness, reconstituted in water, and

r
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clarified by treatment with activated charcoal followed by centrifugation (3000 g, 20
. )

nun. ·

The hydrolysates were then assayed for hydroxyproline concentration by the

spectrophotometric method of Woessner (1961).

Data were expressed as nmol

bydroxyproline per g wet weight tissue.

E.

ISOLATION

AND

PRIMARY

CULTURE

OF

NEONATAL

RAT

VENTRICULAR MYOCYTES.

1. Coating Cell Culture Plates.
Collagen Stock Solution (20x): Acid soluble collagen was dissolved in 1: 10 diluted
Swim's-S77 (pH 4.2) and stirred overnight at 4 cc until it was completely dissolved. The
final concentration was adjusted to stock solution 0.5 mg/ml and stored at -20 cc in
aliquots.
Cell culture dishes were pre-treated with collagen (Engelmann and Fierer, 1982). The
collagen stock solution was thawed and diluted with Swim's-S77 to a final concentration
to 25 µg/ml. A recommended amount of collagen solution (1.5 ml for 35 mm dish or
each well of a 6 well plate, 6 ml for 100 mm dish) was added onto the plate. The plate
was swirled to cover the bottom and left at 4 c C overnight. The remaining solution was
aspirated, fresh Swim's-S77 solution was added, and the plates were stored at 4 c C.
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2. Cell Isolation Protocol.

Neonatal ventricular myocytes were isolated from the hearts of 2-day-old rats by the
collagenase digestion method (Engelmann et al., 1990). Neonatal rat pups, at postnatal
day 1 to 2, were decapitated into liquid nitrogen, bodies washed with 70% ethanol, and
the chest cavity opened to expose the heart. The beating hearts were rapidly removed and
placed into ice-cold, C02 -equilibrated perfusion buffer without collagenase and Ca2+
(Table 4). Hearts were collected and ventricles were trimmed free of atria and major
blood vessels, washed in fresh 37° C perfusion buffer and minced with an alcoholcleaned new razor blade. About 6-10 hearts were placed into each 25 ml Erlenmeyer
flask containing 5 ml of enzyme/calcium-free perfusion buffer and 5 ml of perfusion
buffer with collagenase and calcium for the first 15 min incubation. The perfusion buffer
containing 0.1 mM CaCh was pre-warmed to 37° C overnight in a 5 % C0 2 tissue culture
incubator and the next morning, 0.5 mg of collagenase/rnl was added to make enzyme
digestion perfusion buffer.
Tissue fragments were shaken at 100 to 125 rpm for 15 to 23-minute incubations at
37° C. Cells, cell debris, and residual red blood cells that were released during the first
15-minute incubation were aspirated off and discarded. Another 8-10 ml of enzymecontaining perfusion buffer was added, tissue fragments were incubated for 18 min, and
again released cells/tissue debris were discarded. Fresh enzyme digestion buffer (8-10
ml) was added, and incubated for 15 min. Then tissue fragments were triturated several

times with a sterile, large-bore plastic transfer pipette, and incubated for an additional 7
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min. After 22 min of digestion, tissue fragments were allowed to settle by gravity for 0.5
min, and all released cells were collected from the supernatant using a transfer pipette.
Released cells were filtered through a sterile 40 mm nylon mesh that was washed with 3
ml of enzyme free buffer. Fresh enzyme containing buffer (8-10 ml) was added to the
tissue fragments and this step was repeated two more times.
The cells released after each dissociation were isolated by centrifugation (50 x g, 4
min, RT), and resuspended in 5 ml enzyme free perfusion buffer. The resuspension was
added to a 50 ml collection tube containing 12.5 ml perfusion buffer, 90 µl fetal bovine
serum and 125 µl of 0.5 M EDTA and stored on ice. At the second collection, another
125 µl of 0.5 M EDTA was added to the collection tube. After the final collection, the
volume was brought to 30 ml and total cell yield was determined using a hemocytometer.
All released cells were collected by centrifugation, and resuspended in PC-1 medium.

3. Cell Culture

Released cells were plated onto collagen-coated dishes in undiluted PC-1 medium and
left undisturbed in a 5% C0 2 incubator for 18 h. Unattached cells were then removed by
aspiration. The cell layer was gently washed with HBSS. Growth medium (a 2: 1 mixture
of DMEM/F12:PC-1) was added. Verapamil, PMA or other agents were added at this
time. Myocytes were then maintained in serum-free culture for up to 96 h with daily
medium replacement.

58

TABLE4
Perfusion Buffer For Neonatal Rat Ventricular Myocyte Isolation.

(Ll(l)MB(l)NENT

AM(l)TJNIJ (mgtl)

(30N(UENIJR.ATIDN

HEPES

2,400

lOmM

Pyruvate, Na-Salt

1,100

L-Glutamine

730

Nicotinamide

120

lmM

L-Ascorbate

70

0.4mM

Adenosine

270

D-Ribose

150

lmM

MgCh

240

lmM

Taurine

375

lOmM
5mM

---

-

----·--·-

DL-Carnitine

-

------- --·-·--

I

!

i

!

----1
i

lmM

!

lmM
-----~-------

-

Potassium Bicarbonate

400

2mM

2,600

26mM

l

-

!
!'
I

JoklikMEM

1 package

Gentamycin

1 ml (lOOOx)

Final pH

7.3-7.4

·---·-

10 µg/ml

I
I

I

II

This buffer was made up with 0.5 mg collagenase/ml and 0.1 mM CaCh when used for
cell isolation and tissue digestion.

59

F. TOTAL RNA ISOLATION FROM RAT LV TISSUES AND CULTURED
NEONATAL MYOCYTES.

Total RNA was isolated from L V tissue and cultured neonatal myocytes by the method
of Chomczynski and Sacchi (1987). For tissue samples, approximately 50 mg of frozen
LV tissues were homogenized in 1 ml of Guanidine thiocyanate solution (GIT= 4 M
Guanidine thiocyanate, 25 mM Na citrate, 0.5% Sarcosyl and 0.1 M

~-mercaptoethanol)

in a polypropylene tube for 30 sec. and made up to a final volume of 3 ml by adding
another 2 ml GIT solution to the tube. For cultured cells, 100 mm dishes were washed
with cold HBSS twice, scraped in 3 ml GIT solution. Then, 300 µl of 2 M NaOAc (pH
4.0), 3 ml of phenol and 600 µl of chloroform:isoamyl alcohol (49: 1) were added to the
tube with mixing after each addition, incubated on ice for 15 min, centrifuged at 10,000 x
g for 20 min at 4° C. The aqueous (top layer) phase was mixed with an equal volume of
isopropyl alcohol to precipitate nucleic acids at -20° C overnight. The RNA was pelleted
by centrifugation at 10,000 x g as before, and resuspended in 400 µl of GIT solution. The
RNA was precipitated again by mixing with 600 µl isopropyl alcohol, pelleted by
centrifugation, washed with 70% ethanol and dried in a Speed Vac concentrator. The
final RNA pellet was re-dissolved in 1 mM EDTA and stored at -70° C for Northern blot
analysis.
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G. SPECTROPHOTOMETRIC QUANTIFICATION OF DNA OR RNA

A small aliquot of the DNA or RNA sample was quantified by UV spectrophotometry.
The readings at wavelengths of 260 nm and 280 nm were taken. An OD reading of 1.0 at
260 nm corresponding to approximately 50 µg/ml of double stranded DNA, or 40 µg/ml
single stranded RNA. The purity of DNA and RNA preparations was estimated by the
ratio of the readings at 260 and 280 nm (OD26o/OD2so). Pure preparations of DNA and
RNA have OD26o/OD2so ratios between 1.8 and 2.0.

H. AGAROSE GEL ELECTROPHORESIS

1. DNA Agarose Gel Electrophoresis
DNA from 500 bp to approximately 10 kb in length can be separated on agarose gels
of various concentrations (0.8-1.2%, w/v). Agarose was dissolved in Ix TAE buffer (50x
TAE buffer (1 L): 242 g Tris base, 57.1 ml glacial acetic acid and 100 ml 0.5 M EDTA,
pH=8) by boiling, and cooled to 55° C. Ethidium bromide (EB) was added to a final
concentration of 0.5 µg/ml and mixed thoroughly before casting the agarose solution in
an appropriate size gel apparatus.

The gel was allowed to set completely at room

temperature, and depending on the agarose concentration, complete solidification
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occurred in 30 to 60 min. The solidified gel was submerged in lx T AE buffer until
electrophoresis.
DNA samples were mixed with 6x loading buffer (0.25 % bromophenol blue, 0.25 %
xylene cyanol FF and 40 % (w/v) sucrose in H20) and loaded into the wells of the
submerged gel. One or more DNA molecular weight standards were also included in
each gel. The gel was electrophoresed at 1-5 volts/cm. The DNA bands were viewed
under UV light and photographs were taken by using a photographic transilluminator
system.

2. RNA Agarose Gel Electrophoresis

Agarose gels (l.2%, w/v) were prepared in the same way as the gels used for DNA
electrophoresis except that agarose was dissolved in lx MOPS solution (lOx MOPS
solution: 0.2 M MOPS, 0.05 M sodium acetate, 0.01 M EDTA, pH 7.0). After cooling to
55° C, 37% of formaldehyde (final concentration = 5%, v/v) and EB were added to the
solution.
For Northern blotting, RNA samples (10 µg) were denatured in lx MOPS, 5%
formaldehyde and RNA loading dye (6x loading dye: 50 % glycerol, 1 mM EDTA
(pH=8.0), 0.25 % bromophenol blue) at 65° C for 10 min The denatured RNA samples
were chilled on ice and centrifuged for 3 sec to deposit all of the fluid in the bottom of the
microfuge tube. The RNA samples were loaded into the preformed wells. The gel was
run at 100 volts for 1-2 h until the dye front reach to the end of the gel. RNA was
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quantified by absorbance at 260 nm and the integrity was determined by examining the
28S and 18S rRNA bands in ethidium bromide-stained agarose gels visualized under UV
light.

I. NORTHERN BLOTTING.

Following electrophoresis of RNA, the agarose gels were prepared for transfer by
soaking in denaturing solution (0.15 M NaCl, 0.05 M NaOH) for 45 min followed by
neutralizing in 0.15 M NaCl, 0.1 M Tris-HCI solution for 30 min

The RNA was

transferred to nylon membranes (Micron Separations Inc., Westboro, MA) by capillary
action with lOx SSC overnight. After transfer, the nucleic acids were cross-linked to the
membrane using an UV cross-linker (Stratagene).
The membranes were hybridized with cDNA and oligonucleotides probes as follows.
The RNA blots were prehybridized for several hours at 42° C in cDNA hybridization
solution (50 % deionized formamide, 10 % Dextran sulfate, 1 % SDS, 1 M NaCl, and 100
µg/ml salmon sperm DNA (heat denatured by boiling 5 min)) and then hybridized
overnight at 42° C with labeled probe in the same solution. After hybridization, the
membranes were washed initially with 2x SSC and 0.5 % SDS at room temperature for
10 min (4 times). The final washes were in O.lx SSC and 0.1 % SDS at 60° C. All blots
were exposed to MP film (Amersham) with intensifier screens at - 70° C for varying time
periods. Band intensity was quantified using an LKB Ultrascan XL Enhanced Laser
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Densitometer interfaced to a personal computer running Gelscan XL (Ver. 1.21). Band
intensity of the SERCA2, MHC-a and MHC-~ signals were expressed relative to the
intensity of the constitutively expressed gene GAPDH.

J. FILTER STRIPPING AND REPROBING.
In order to reprobe the blots with several cDNA or oligonucleotide- probes, the

hybridized blots were stripped by incubating in 0.5 % SDS at 85° C for 45 min The blot
can be reprobed several times after stripping.

K. PREPARATION OF cDNA PROBES:

1. Transformation of Plasmid DNA into Bacteria.

To obtain large quantities of plasmid DNA, E. Coli bacteria were transformed by
plasmid and allowed to multiply. DH5a bacteria were removed from -80° C and thawed
on ice for 15 min.

100 µl of competent cells were placed into a chilled sterile

polypropylene culture tube. 100 ng of plasmid DNA dissolved in 1 µl TE buffer was
gently added onto thawed bacteria. After incubating on ice for 30 min, the cells were
heat shocked at 42 °C for 45 sec, and again chilled on ice for 2 min. Then 0.9 ml sterile
LB broth and 2 µl of 25 mg/ml ampicillin were added into the culture tube. The bacteria

r
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were allowed to grow at 37° C for 1 h in a shaking incubator (225 rpm). Finally, the
bacteria were spread out on· an ampicillin agar plate and incubated in a 37° C incubator
for 14-16 h to select for transformed bacteria.

2. Plasmid DNA Isolation

a). Small Scale Preparation of Plasmid DNA. To isolate small amounts of plasmid
DNA from transformed bacteria, a rapid boiling method for the preparation of bacterial
plasmids was employed (Holmes et al., 1981). A single bacterial colony was transferred
into 5 ml of LB medium containing the appropriate antibiotic in a loosely capped 15 ml
tube. The culture was incubated overnight at 37° C. A small volume of bacteria (0.5 ml)
was stored at 4 ° C for large scale preparation of plasmid DNA. The rest of the bacteria
were pelleted at maximum speed in a microcentrifuge for 30 s, and the supernatant was
aspirated. The pellet was resuspended in 50 µl of lysis buffer (10 mM Tris-HCI, pH 8.0,
1mMEDTA,0.1 mg/ml bovine serum albumin, 15 % wt/vol. sucrose, 2 mg/ml lysozyme
and 0.2 mg/ml pancreatic RNase) and incubated at 37° C in a shaker for 5 min. The
suspension was boiled for 60 sec and immediately chilled on ice for 60 sec.

After

centrifugation at maximum speed for 20 min at 4 ° C in a microcentrifuge, the supernatant
was transferred to a clean tube and made ready for digestion with restriction enzymes to
check the identity of the plasmid.
b ). Large Scale Preparation of Plasmid DNA. The large scale preparation of plasmid
DNA was prepared according to a modified alkaline lysis procedure (Birnboim and Doly,
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). After confirming the identity by restriction analysis of the small scale plasmid
1979

vNA preparation, the bacteria was cultured in 200 ml LB at 37° C overnight. The
pas
I

mid DNA was purified by using a QIAGEN plasmid purification kit and was loaded

into a Centricon-30 concentrator (Amicon, Inc. Beverly, MA), diluted with Milli-Q H 20
and then centrifuged at 3000 rpm for 25 min (2x at room temperature), to remove all the

excess salt and concentrate the DNA. The purified plasmid DNA was stored at -20 °C for
future use.

3. Isolation of cDNA Inserts

The specific cDNA insert was cut out from the plasmid vector by appropriate
restriction enzyme digestion. The mixture of DNA and enzyme solution was fractionated
on an agarose gel. After identifying the correct band, the band was cut out and put into a
clean dialysis membrane tubing (Spectrum Medical Industries, Inc. Los Angeles, CA.).
The DNA fragments of the correct size were then eluted into the dialysis tubing
containing 0.5x TAE. The electrodes were reversed briefly (10 sec.) to get any DNA
fragments bound to dialysis tubing back into solution.

The DNA fragments were

collected and underwent further purification as described above (section K-2b).

4. 32P-Labeling of Hybridization Probes
a). Labeling Double-Stranded DNA with Random Hexamers. Human GAPDH cDNA

clone and rat SERCA2 cDNA clone to be used as cDNA probes for hybridization were
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labeled to high specific activity with (a- P) dCTP using the multi-prime DNA labeling
method (Feinberg and Vogelstein, 1983). In this method, random oligonucleotides were
used to prime DNA synthesis in vitro by using denatured linear double-stranded DNA
fragments as the template.

Over 70% of the precursor triphosphate was routinely

incorporated into complementary DNA, and specific activities of over 109 dprnlµg of
DNA were obtained.
The multi-prime labeling system was used to label the cDNA probe for Northern
blotting analysis. In the 50 µl volume reaction, 100 ng of denatured DNA fragments was
used as the template. The reaction mixture also contained buffer, primer, equal molar
quantities of unlabeled dGTP, dATP, dTTP, 50 µCi (a- 32P) dCTP and 5 U Kienow DNA
polymerase enzyme. The reaction mixture was gently mixed and incubated at 37° C for
30 min The reaction was stopped by adding 2 µl of 0.5 M EDT A and chilled on ice.
Before the probe was added into the hybridization tube, radio-labeled DNA fragments
were denatured by heating at 100° C for 3 min with subsequent chilling on ice.
b).5'-end labeling of DNA oligonucleotides. 40-base oligonucleotide probes specific
for the 3' untranslated regions of the rat MHC-a and MHC-~ genes were used to quantify
MHC mRNA levels (Pope et al., 1980). An oligonucleotide probe specific for rat 18S
rRNA was used for verifying equal loading conditions of Northern blots in the BDM
experiment and actinomycin D experiment. The oligonucleotide probes were end-labeled
with (y- 32P) ATP using T4 polynucleotide kinase. In the 30 µl volume reaction, 240
pmole of oligonucleotide was mixed with kinase buffer (lOx buffer: 50 mM Tris-HCI,
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pH 8.0, 10 mM MgClz, and 5 mM dithiothreitol (DTT)), 20 µCi (y-

32

P) ATP and 10 U T4

Kinase. The reaction mixture was gently mixed and incubated at 37° C for 60 min. The
reaction was stopped by adding 2 µl of 0.5 M EDT A and chilled on ice.

5. Quantification of 32P Incorporation
To test the amount of

32

P incorporation, two 1 µl aliquots of the labeled reaction

mixture were added to 2 pieces of Whatman filter paper separately. One of them was
washed in 0.5 M Na2HP0 4 solution twice (5 min/each) and then washed in Milli-Q H20
for 5 min. The washed and unwashed filter papers were counted in a W ALLAC BETA
counter. The percent of 32P incorporation was calculated by: cpm of washed filter/ cpm
of unwashed filter. The incorporation rates were generally greater than 70 %. The probe
was added to the hybridization tube to the final concentration of 106 incorporated cprn/ml.

L. POLYMERASE CHAIN REACTION

To analyze the effect of PMA and veraparnil on the rate of SERCA2 gene expression,
a fragment of the SERCA2 promoter region was generated by using two oligonucleotide
primers (Primer 1: 5'- GGAAGCTTCC TCCCCTTGGT TGCTG-3', Primer 2: 5'GGCCATGGAC AGCGGCGGAG GAAACTG-3' corresponding to the region -5561+60
bp relative to the transcriptional start sites of the rat SERCA2 gene (Figure 3). The
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primers included Hindill and Ncol restriction sites, respectively, to allow for orientationspecific ligation into a promoterless luciferase expression plasmid (pluc, kindly provided
by Dr. Kaie Ojamaa, Cornell University Medical College).

PCR amplification was

performed in a 50 µl volume containing 1 µg genomic DNA, Taq DNA polymerase 2.5
U, amplification primer pair (100 pmol for each) and PCR buffer (pH 8.5, MgCh, 22.5
mM). Samples were overlaid with 50 µl mineral oil to prevent evaporation and were

incubated at 94 ° C for 3 min to allow the first denaturation, followed by the following
cycling parameters for amplification: 94° C, 1 min, 55° C, 30 sec, and 72° C, 2 min. A
total 35 amplification cycles were performed. After 10 min of final extension at 72 °C,
the PCR products were analyzed by agarose gel electrophoresis, which demonstrated a
single fragment of 616 bp.

M. DNA SUBCLONING

1. Restriction Enzyme Digestion

To subclone the rat SERCA2 gene promoter DNA into reporter plasmid pluc, the 616
bp PCR product and the pluc plasmid were sequentially cut with Hindill and Ncol. The
cut PCR product was further purified using a Centricon-30 concentrator as described
above (section K-2b). The cut plasmid mixture was loaded on an agarose gel and the
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5734 bp fragment of the plasmid DNA was collected as promoter vector (detailed
procedure see section K-3 ).

2. Ligation and Transformation

Ends-compatible insert and vector were ligated together by T4 DNA ligase under the
following conditions. In a total volume of 30 µl, 150 ng vector was mixed with insert in
a 1:3 molar ratio in the presence of 50 mM Tris-HCl, pH 7.6, 10 mM MgCh, 1 mM
ATP, 1 mM DTT, 5% (w/v) polyethylene glycol-8000, and 1 U T4 DNA ligase. The
ligation reaction mixture was incubated at 16° C overnight (Figure 4) and yielded
pSERCA-luc.
The pSERCA-luc plasmids were then transformed into E.Coli bacteria as described
above (section K-1). Then a small scale plasmid preparation was made to identify the
plasmid. Finally, a large scale plasmid preparation was made and purified for sequencing
and transfection assay.
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BASE COUNT

88 A

234 C

241 G

72 T

Primer 1 ~
GAATTCCTCC CCTTGGTTGC TGAGGGGGGC TCTGAAGGAG ACATTAGGAT GCAGAGCACG
GCTCGCGCTG CCCAGGGCGC GGAGGCAAGC CAAGGACACC AGTCCCTGCG CGCCTCGGTC
CCCAGCGTTC CGGCGCCTCC CTGCCACCAC GCGGCCCCAG GAAGTCCCCC CTCAGCGGCG
GGGCCCCCAG CACAGAGCGC CCACCCGTGA GCTCCGCGAT CTATTCCTGC ACGCGGACGG
AATGGGAAAG CCGCGACCGC GTAAGGTCGG GCTCGCCCTC CGCCCGCCCG GCCGCAGCG
AGCACAGCGA GGACGCGGAG GTGGCCTGCG CGCGCACACG CGCGCGGCCT CGATCCGGGT
TACTGGGGGC GGCGCGCGGG AGGAGGCGGG GCCTGCCGGC AGCGTGGGCG CGCACGCGCC
GCGGGAGGGC GCCGGGGGAG GGGGCGGGGC CGCGCCGCCC GCGCCGCGCT GGGCTCTCTC
GGCCAATGAG CGGCGTCCAC ATGCCCGGCG GCGGCGAGAG GGGAGGCAGC GGCGGATAAA
TGCTATTAGA GCAGCCTCCG CGGAGCCGTC CCCGACGCCA CCTCCCGTCT

CCTCCGCCG~

AGTTTCCTCC GCCGCTGTCG GGGGTGCAGA GCTGA
~

Primer2.

Primer 1 (25 hp)
-556

-538
5' GGAf GCTTCCTCCCCTTGGTTGCTG 3'
Hind Ill

Primer 2 (27 hp)
+60

+41

5' GGCfATGGACAGCGGCGGAGGAAACTG3'
Ncol

Figure 3: Sequence of 5' region of SERCA2 gene (Hartong et al., 1991) and the two
primers used for PCR cloning of SERCA2 gene promoter.

71

Illustration for SERCA2 Promoter Transfection Assay
Ncol

'

~,___ _ _ _ _
L.--i__.

'

Hind III

DNA insert (616 bp)

Luc iferase
Promoterless reporter gene

Promoter+reporter gene
chimeric plasmid

'
'

Transfect the cells
Reporter gene product assay

Figure 4: Illustration of the SERCA2 promoter transfection assay protocol.
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N. DNA SEQUENCING

The inserted promoter was sequenced using a sequenase version 2.0 DNA sequencing
kit based on the chain-termination DNA sequencing method (Sanger et al., 1977).

The

sequencing strategy used in this study was to sequence this 616 bp PCR product from
both DNA strands using two oligonucleotide primers encoding the

pluc plasmid

sequences from 5' up-stream and 3'down-stream of the promoter insert, respectively. In
this case, PA-3 (5' TGGCAGATTA TGATCAG 3') and LU-1 (5' ATGCAGTTGC
TCTCCAGCGG TT 3'), kindly provided by Dr. Kaie Ojamaa (Cornell University
Medical College), were used to sequence the positive and negative strand of this PCR
product respectively. A 17 bp primer (5'GCCGCGACCG CGTAAGG 3' obtained from
Dr. Bassam Wakim, Loyola University Medical Center) corresponding to the rat
SERCA2 promoter region -310/-293 was also made to sequence the middle part of this
DNA fragment.

The sequencing procedure was outlined as following.

Supercoiled

plasmid DNA was denatured by a 0.2 M NaOH, 0.2 M EDTA solution for 30 min at 37°
C and neutralized by adding 0.3 M Na Acetate solution, pH= 5.2. The denatured DNA
was pelleted and air-dried and resuspended in a given volume of Milli-Q water. To
anneal denatured plasmid DNA with sequencing primer, 2 µl of sequencing buffer was
added to the 7 µl of DNA and 1 µl of primer (10 ng/µl) and incubated at 37 °C for 30
min. To label the primers, 1 µl of 0.1 M DTT, 1 µl of 35 S-adATP, 2 µl of dilute labeling
solution and 2 µl of dilute sequenase version 2.0 T4 DNA polymerase were added to the
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annealed reaction mixture and incubated at room temperature for 10 min After labeling,
3.5 µl of the above mixture was added to the side of each termination tube which contains
d/ddNTP. The mixture was incubated at 37c C for 10 min. The reaction was stopped by
adding 4 µl of stop solution and cooled immediately on ice. The samples were denatured
at soc C for 5 min immediately before loading. Half of the reaction volume was then
loaded on a 6 % polyacrylamide sequencing gel (15 ml 40 % acrylamide stock solution,
20 ml 5x TBE, 25 ml dH 20, 5 g urea, 1ml10% APS, 35 µl TEMED). The gel was run at
55 W for 2 h with lx TBE buffer using a Jordan Scientific Co. sequencing apparatus.
The second half of the reaction was loaded on the gel for another 2 h electrophoresis. At
the end of electrophoresis, the gel was fixed in 10 % acetic acid and 10 % methanol for
15 min After fixation, the gel was adhered to a 3 MM Whatman paper, covered with
Saran wrap, dried at soc C for 30 min, then exposed to an X-ray film.

0. TRANSIENT TRANSFECTION ASSAY.

1. Transfection

For DNA transfection, two plasmid constructs were used. pRSVlacZ, which contains
the E Coli

~-galactosidase

gene under control of a rous sarcoma virus (RSV) enhancer

was used as an internal standard for normalization of transfection efficiency. pSERCAluc, as the promoter-reporter gene construct plasmid, contains the promoter element of
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the SERCA2 gene and a promoter-less reporter gene encoding firefly luciferase.
Neonatal rat myocytes were plated onto 6 well dishes ( l.2x 106) and maintained
overnight in PC-1 medium. The DNA solution was prepared by adding pSERCA-luc (5
µg/well) and pRSV~gal plasmid (0.5 µg/well) into Optimem I solution to a final volume
of 100 µI/well.

Lipofectamine solution was prepared by adding 15 µg/well of

Lipofectamine into Optimem I solution in a final volume of 100 µl.

Then the DNA

solution was mixed with lipofectamine solution and incubated at room temperature for 15
min. The liposome-DNA mixture was diluted with 2: 1 medium containing 12 µg/ml
gentamicin and then the liposome-DNA mixture was added to a triplicate set of plates.
The cells were cultured in antibiotic-free medium for 6 h and then maintained in normal
growth medium with or without PMA or verapamil for 48 h.

2. Harvesting

The transfected cells were then washed with ice-cold HBSS, and 500 µl of lysis buffer
(25 mM Tris-phosphate, pH 7.8, 2 mM DTT, 10 % glycerol, and 1 % Triton X-100) was
added. Cells were scraped off the dishes, and the lysate was centrifuged at 12,000 rpm
for 10 min in a cold room to remove insoluble debris. The supernatant was collected and
placed on ice for the luciferase and

~-galactosidase

assay.
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3. Luciferase Assay

The luciferase assay was performed as described (Ojamaa and Klein, 1991). 100 µl of
sample was added to 500 µl 2x luciferase assay buffer (50 mM Tris-acetate pH 7.8, 10
mM magnesium acetate, 2 mM ATP, 25 mM DTT, 1 mM EGTA). 300 µl of water and

100 µl of luciferin (2 mM) was automatically injected into the sample immediately before
counting. Luminescence was measured in a luminometer.

4. p-galactosidase (p-gal) Assay
P-gal activity in the cell extracts was assayed according to the method of Miller, with
o-nitrophenyl-P-D-galactopyranoside (ONPG) as the substrate (Miller, 1992). 200 µl of
sample was mixed with p-gal assay buffer (2.5x p-gal assay buffer: 48 mM Na2HP04 , 32
mM NaH 2P04 , 8 mM KCl, 0.8 mM MgCh and 14.28 µ1110 ml of P-mercaptoethanol) and

200 µl of ONPG to make a final volume of 1 ml and incubated in 37° C water bath for 3
hours.

The reaction was stopped with 200 µl of 2M Na2C0 3 and vortexed.

The

calorimetric reaction was detected at 420 nm in a spectrophotometer using water as the
blank.

5. Expression of Data
Luciferase activity was presented as background-subtracted units divided by the
control p-gal activity to normalize for the differences in transfection efficiency.
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P. ACTINOMYCIN D (act-D) mRNA STABILITY ASSAY.

The relative stability of SERCA2 mRNA in control and veraparnil or PMA treated
cells was assessed following treatment of myocytes with act-D. Neonatal myocytes were
maintained in growth medium in the absence or presence of PMA (200 nM) or veraparnil
(10 µM) for 24 h. Act-D (5 µg/rnl) was then added , and the cells maintained for an
additional 0, 12 or 24 h at which time total RNA was isolated by the method of
Chomzynski and Sacchi (1987). RNA was quantified, size-fractionated and analyzed by
Northern blotting with probes specific for SERCA2 and 18 S rRNA as described above.
Band intensity was quantified by laser densitometry.

Q. DNA AND PROTEIN ASSAY.

Total cellular protein and DNA content of the samples (from LV tissue and cultured
neonatal rat ventricular myocytes) were measured by the Lowry (Lowry et al., 1951) and
Bisbenzirnid assays (Cesarone et al., 1979), respectively. The cells on 35 mm dishes
were washed twice in HBSS, and 0.2 N perchloric acid (1 ml) was added to the culture
well. The precipitated macromolecules were then quantitatively scraped from the dishes,
and collected by centrifugation (10,000 g; 10 min). The precipitate was washed with 0.2
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N perchloric acid once and redissolved by incubation (37° C, 20 min) in 1 ml of 0.3 N
KOH. Aliquots were then used for analysis of total protein by the Lowry method using
crystalline human serum albumin as a standard. For DNA assay, 33258 Hoecht dye and
salmon sperm DNA standard were used in Bisbenzimid assay. Data are the means of
duplicate or triplicate wells from each treatment group of each cell isolation, and were
expressed as µg/dish. For tissue samples, 5 % of tissue homogenate was made in 0.9 %
saline solution and a 50 µl aliquot of the sample was used for the Lowry protein assay.

R. QUANTITATIVE ANALYSIS OF TOTAL MHC AND MHC ISOENZYMES.

1. Quantification of Total MHC Protein by Sodium Dodecyl Sulfate
Polyacrylamide Gel Electrophoresis (SDS-PAGE).
For quantitative analysis of total MHC (MHC-a and

MHC-~)

protein content, cells in

35 mm dishes were washed twice in HBSS and lysed in 500 µl of Laemmli sample buffer
(62.5 mM Tris-HCl, pH 6.8, containing 0.01 % bromophenol blue, 8% SDS, 5% 2mercaptoethanol, 10% glycerol). The protein samples were denatured by heating to 100°
C for 20 min. Equal volumes (80 µl) were loaded onto 2.7 mm x 180 mm SDS-PAGE
gradient (7 .5-17%) gel along with additional lanes containing known amounts ( 1-10 µg)
of purified cardiac MHC. The gel was run in SDS gel running buffer (25 mM Tris, 192
mM glycine, pH 8.3, containing 0.1 % SDS) at 12.5 mA per gel, 12° C overnight until the
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bromophenol blue dye marker migrate to the bottom of the gel and then stained in 0.1 %
Coomassie brilliant blue (CBB, 0.1 g CBB in 100 ml methanol: H 20: acetic acid, 5:5:2).
Band intensity was quantified by laser densitometry and compared to the band intensity of
purified MHC standards. Results were the means of duplicate wells from each treatment
group for each cell isolation, and expressed as µg MHC/dish.

2. Quantification of MHC Isoenzymes by SDS-PAGE and Silver Staining

To quantify the relative proportions of MHC-a and MHC-~ isozymes in LV tissue and
cells, equal volumes (15 µl) of protein samples prepared in Laemmli sample buffer were
loaded onto a 5 % acrylamide SDS-PAGE gel along with a known amount of protein
rainbow standard. The gel was run at 12° C, 35 mA/per gel for 3 h until the MHC band
in the rainbow standard runs to the 2/3 of the length of the gel. The gel was carefully
taken off and soaked in 50 % methanol overnight. The next day, the gel was stained
using modified silver staining technique (Guevara et al., 1982).

Band intensity was

quantified by laser densitometry.

S. WESTERN BLOT ANALYSIS.

For quantitative analysis of SR Ca ATPase protein content, samples were prepared in
Laemmli sample buffer as described as above.

Equal amounts of protein (20 µg
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protein/lane) were loaded onto and electrophoresed through a 7.5% SDS-polyacrylamide
gel at 100 Volts in SDS gel running buffer for about 1.5 h until the bromophenol blue dye
marker migrated to the bottom of the gel. Proteins were electroblotted to nitrocellulose
sheets in 1 x SDS-PAGE running buffer with 20 % of methanol at 80 V for lh (Towbin et
al., 1979). The blot was prepared for antibody analysis by soaking in blocking solution
(5% non fat milk solids (NFMS) and lx TBST [lOx TBST: 0.1 M Tris-HCl, pH 8.0,
0.75 % Tween 20 and 1.5 M NaCl]) overnight at 4° C.

Rabbit anti-rat SERCA2

antiserum was diluted 1: 1000 in TBST with 5 % NFMS. The blot was incubated with
primary antiserum solution for 1 h at room temperature, rinsed with TBST and washed in
TBST for 5 min 3 times, then incubated in TBST containing 5 % NFMS for 15 min The
secondary antibody, anti-rabbit IgG conjugated with horseradish peroxidase (diluted in
blocking solution 1:5000) was added to the blot and incubated at room temperature for 1
h. The blot was washed as above, then placed on a glass plate. After removing all the air
bubbles, equal amounts of detecting solutions from the Chemoluminescence kit were
added onto the blot and immediately covered with saran wrap for 1 min. The film was
developed after placement on top of the covered blot for 1-5 min. The band intensity was
quantified by laser densitometry.
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T. DATA ANALYSIS.

All results were expressed as means±SEM. Data were analyzed using the PROPHET
computer system software (Division of Research Resources, NIH). The data were tested
for normality by Wilk-Shapiro test followed by Levene's test to examine the equality of
variances. If the data passed both tests, one-way analysis of variance (ANOVA) followed
by the Student-Newman-Keuls test were used for multiple comparisons and two-way
ANOV A was used to test the factors "PMA" and "contraction" and their interaction on
measurements of growth and gene expression. If the data were not normally distributed,
or if the variances were not homogeneous, then the Kruskal-Wallis test followed by
Dunn's test was used for comparisons among sham, 8 wk haded and 16 wk banded
groups in the whole animal study and Friedman repeated measures analysis of variance on
ranks followed Student-Newman-Keuls test was used to analyzed the effects of verapamil
and PMA on the SERCA2 promoter activities in the transient transfection study.
Nonlinear regression analysis was used to estimate the half life of SERCA2 mRNA in the
message stability assay. The paired and unpaired t-tests were also used for comparisons
of parametric data between two groups. In each case, significance was accepted at p
<0.05.

CHAPTER IV
RESULTS

A. DO CHANGES IN SERCA2 GENE EXPRESSION AFFECT CARDIAC
PERFORMANCE DURING LVH PROGRESSION?

1. Abdominal AoC Produced Hypertension and LVH.

A total of 45 male Sprague-Dawley rats (14 sham-operated sham and 31 banded rats)
were used in this study. Surgical procedures were conducted on 3 separate occasions.
Perioperative mortality (defined as mortality within 72 h of surgery) was 0% in the shamoperated group, but ranged from 0 to 30% in the banded group. Thereafter, 100% of the
sham-operated animals and approximately 80% of the banded animals survived until
evaluation at either 8 or 16 weeks. Both sham and banded animals were evaluated at each
of these time points, but since none of the morphometric, hemodynamic or biochemical
measurements differed significantly between 8 wk and 16 wk sham rats, the data from all
sham animals were pooled for the sake of clarity.
As seen in Table 5, coarctation of the abdominal aorta produced significant increases
m systolic arterial pressure (SAP), diastolic arterial pressure (DAP) and mean
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arterial pressure (MAP) measured 8 wk after banding, as compared to sham-operated
controls. Thereafter, blood pressure measurements did not change significantly.
Sustained hypertension was associated with the development of LVH. The LV/body
weight ratio was 38% greater in 8 wk banded rats as compared to sham-operated animals
(2.15±0.15 and 2.96±0.17 mg/g for sham and 8 wk banded rats, respectively; P<0.01).
The LY/body weight ratio was also significantly (P<0.01) increased (by 45%) in 16 wk
banded animals (3.13±0.14 mg/g) as compared to sham animals. However, LV/body wt
ratio was not statistically different between 8 and 16 wk banded animals.

2. Abdominal AoC Produced Alterations In Cardiac Performance.

I next evaluated whether sustained hypertension was associated with the development
of systolic and/or diastolic dysfunction over time.

High-fidelity recordings of L V

pressure were obtained using a manometer-tipped, 3F catheter advanced from the right
carotid artery to the LV chamber, and the digitized data analyzed with respect to indices
of systolic and diastolic performance. As seen in Table 5, +dP/dtmax and contractility
index (CI) were not significantly altered in either 8 wk or 16 wk banded animals,
indicating that isovolurnic systolic function was relatively normal despite increased
afterload and LVH. In contrast, the banded rats demonstrated abnormalities in diastolic
function, especially at 16 weeks. The -dP/dtmax was decreased in both 8 wk and 16 wk
banded rats, but these differences did not attain statistical significance. Since -dP/dt is
afterload-dependent (Lorrell, 1991), individual values from the 3 groups were normalized
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by dividing by the MAP, as previously described (Burgess et al., 1995). As seen in Table

S, normalized -dP/dtmax was significantly (P<0.01) reduced in both 8 wk and 16 wk
banded animals, but there was no significant difference noted between 8 and 16 wk
banded rats. The relaxation time constant

't

was also prolonged in both 8 and 16 wk

animals however, statistical significance was only found in 16 wk banded rats (P<0.01) as
compared to sham-operated controls.
In contrast, LVEDP was relatively normal in 8 wk banded rats, but was significantly
(P<0.01) elevated in 16 wk banded animals. The elevated LVEDP indicated that cardiac
performance in 16 wk banded animals had deteriorated without a further increase in LV
mass, worsening hypertension, or evidence of isovolumic systolic dysfunction. Thus,
these 16 wk animals were considered to be in a "transitional" phase between stable or
compensated LVH and heart failure.
The observed increases in

't

and LVEDP in pressure-overloaded animals were not the

result of acute changes in afterload, but were dependent upon changes in myocardial
structure or function that developed over time. As seen in Figure 5, partial occlusion of
the abdominal aorta of a normal rat at the identical site of aortic banding caused an acute
increase in systolic arterial pressure, but had no effect on either
(Panel B).

t

(Panel A) or LVEDP
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TABLES
Hemodynamic Measurements In Sham and Banded Rats

130±6
(n=14)
DAP(mmHg)
88±5
(n=l4)
MAP(mmHg)
102±5
(n=14)
8057±411
+ dP/dtmax (mm Hg/sec)
(n=14)
Contractility Index
115±3
i
(n=lO)
...................·-·····-·---·--·-··············--······.. ······~---····
7411±346
- dP/dtmax (mm Hg/sec) !
(n=l4)
(-dP/dtmax)/ MAP (sec- 1)
74±3
(n=14)
---14.5±0.8
't (msec)
(n=lO)
L VEDP (mm Hg)
3.6±1.0
(n=14)

111±9*
(n=9)
133±11 *
(n=9)
9078±1240
(n=9)
113±16
- (n=8)
6944±818
(n=9)
54±6*
(n=9)
25.7±5.8
(n=8)
7.9±3.1
(n=9)

* P < 0.05 vs. Sham.
SAP = Systolic arterial pressure.
DAP = Diastolic arterial pressure.
MAP = Mean arterial pressure.
L VEDP = Left ventricular end diastolic pressure.
't = The time constant for isovolumic relaxation.
Contractility Index = (+dP/dtmax)ILVP at peak dP/dt.

120±3*
(n=22)
145±4*
(n=22_)_
7921±363
(n=22)
101±8
Cn:=..!.2.L_____
6386±322
(n=22)
46±2*
(n=22)
25.1±2.0*
(n=l4)
15.2±2.1 *
(n=21)
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Figure 5: SAP, LVEDP and 't before and after acute aortic banding. A normal rat was
anesthetized with ketamine-xylazine. Abdominal surgery and carotid artery cannulation
were performed as described in the Methods section. A snare was placed around the
identical site as used for aortic banding. i and J, represent the time at which I tightened
and loosened the snare, respectively.
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3. Changes In Tissue Composition Coincide With The Development Of Progressive
LV Dysfunction.
A growing body of evidence suggests that down-regulation of SERCA2 gene
expression is the most important contributor to the relaxation abnormality during pressure
overload hypertrophy and CHF.

However, there is lack of evidence which directly

associates diastolic function with changes in SR Ca2+ ATPase mRNA and protein levels
during the development of LVH. Therefore, I examined whether alterations in SERCA2
expression coincided with the appearance of diastolic dysfunction during pressure
overload. As seen in Figure 6A, SERCA2 protein levels in 8 wk banded rats were not
significantly different from sham-operated animals, when equal amounts of total protein
from LV tissue homogenates were compared by Western blotting. In contrast, I found a
significant reduction (P<0.05) in SERCA2 protein levels in LV tissue homogenates of 16
wk banded rats as compared to 8 wk banded animals. Because the increase in ECM
collagens (details see next paragraph) may have contributed to dilution of SERCA2
protein within the complex mixture of total tissue proteins, homogenates were prepared
from freshly isolated myocytes of sham and 16 wk banded animals, and also compared by
Western blotting. As seen in Figure 6B, SERCA2 protein levels from 16 wk banded rats
were also significantly (P<0.05) reduced to 66% of control levels in these homogenates.
The decrease in SERCA2 protein levels in 16 wk banded animals was associated with
an even greater reduction in SERCA2 mRNA levels, as analyzed by Northern blotting.
As seen in Figure 7, SERCA2/GAPDH mRNA ratios in 16 wk banded animals were only
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24±9% of those observed in sham-operated control animals (P<0.01).

Interestingly,

SERCA2/GAPDH mRNA levels were also significantly (P<0.01) reduced to 43±10% of
control rats 8 wk after banding, despite the fact that SERCA2 protein levels were
unchanged at this time point.
Above data indicates that the down-regulation of SERCA2 gene was not the primary
cause for the relaxation abnormality in 8 wk hypertensive animals. However, downregulation of SERCA2 gene expression predicted the onset of overt deterioration of
cardiac performance during the development of pressure overload LVH as evidenced by
decreases in SERCA2 mRNA levels prior to markedly elevated LVEDP and a
significantly prolonged

't.

The reduction in SERCA2 mRNA and protein levels that

coincided with the significant increases in LVEDP and

't

after 16 wk aortic banding

indicates that down-regulation of SERCA2 gene expression indeed played an important
role in deterioration of cardiac function during the progression of pressure overload L VH.
Additional factors must contribute to the relaxation abnormalities that occurred in the
compensated LVH.

Since increase in ECM collagen content has been suggested to

responsible for the diastolic dysfunction in chronic hypertensive rats (Burgess et al., 1995
in press), I next examined whether alteration of hydroxyproline contents was temporally
associated with the development of impaired cardiac relaxation in these hypertensive
animals. As seen in Figure 8, I noted 72 % and 49% increase in the amount of proteinbound hydroxyproline in LV tissues of 8 and 16 wk hypertensive rats, respectively. and It
indicated significant (P<0.05) increases in the amount of myocardial collagens 8 and 16

i'
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wk after aortic banding. However, there was no significant difference in hydroxyproline
content between 8 and 16 wk banded animals (Figure 8). These results suggests that
increases in collagen content may account in part for the impaired cardiac relaxation that
occurred after 8 wk of hypertension. However, it may not be related to the deterioration
of cardiac performance during the progression of LVH.
Since a switch in MHC isoenzyme predominance from MHC-a to MHC-B is
characteristic of pressure overload LVH in the rat (Mahdavi and Nadal-Ginard, 1989), the
percentage of MHC-B isoenzyme in LV tissue homogenates was quantified by SDSPAGE, silver staining, and laser densitometry at 8 and 16 wk after AoC. As seen in
Figure 9, 30±3% of the MHC expressed in ventricular muscle of the sham-operated
animals was MHC-B.

The relative concentration of MHC-B was not significantly

increased in 8 wk banded rats, but accounted for 59±3% of the total MHC 16 wk after
aortic banding (P<0.01 vs. sham and 8 wk banded animals, respectively). These results
indicates that MHC isoenzyme switch was unlikely responsible for the impaired cardiac
relaxation occurred in 8 wk hypertension. However, it may in part responsible for the
deterioration of cardiac performance during progressive LVH.

In summary, although my original hypothesis was incorrect, my data are indeed
consistent with an important contribution of SERCA2 down-regulation to the progressive
deterioration in LV performance over time. Therefore, further studies are required to
determine the intracellular mechanisms responsible for SERCA2 down-regulation during
LVH progression, and to elucidate the specific molecular events responsible for
Progressive

diastolic

dysfunction

m

the

pressure

overloaded

heart.
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Figure 6: SR Ca ATPase protein levels in sham and banded rats. Tissue homogenates
(panel A) or isolated myocyte homogenates (panel B) were diluted 4 fold with 8 %
Laemmli buffer. Equal amounts of protein (20 µg/lane) were separated on 7 .5 % SDS-

polyacrylamide gel. SR Ca ATPase protein levels were quantified by Western blotting
using anti-rat SERCA2 antiserum. Data were normalized with the mean value of bands
in sham groups in each gel. Data are the mean±SEM * P< 0.05 vs sham, # P< 0.05 vs 8
wk-B. B= banded by 1-way ANOVA followed by Student-Newman-Keuls test (Panel A),
and unpaired t-test (Panel B).
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Figure 7: Quantitative analysis of SERCA2 mRNA levels in sham and banded rats.
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Figure 9: MHC-~ isoenzyme in sham and banded rats. Tissue homogenate was diluted
4-fold with 8 % Laemmli sample buffer. Equal volumes (15 µl) of diluted tissue
homogenates were separated on 5 % SDS-polyacrylamide gels and the gels were stained
by silver-staining technique. MHC-a and MHC-~ band intensities were quantified by
laser densitometry. Data are expressed as MHC-~/total MHC (MHC-a+MHC-~). Data
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Data are compared by one-way ANOVA followed by the Student-Newman-Keuls test. *
P< 0.05 vs sham,# P< 0.05 vs 8 wk-B. B= banded.
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B.

REGULATION

OF

SERCA2

GENE

EXPRESSION

IN

CULTURED

NEONATAL RAT VENTRICULAR MYOCYTES

1. Neonatal Rat Ventricular Myocyte Cell Isolation and Culture.
The collagenase digestion procedure was used to isolate neonatal rat ventricular
myocytes and routinely yielded 3-4 x 106 cells per neonatal rat heart.

Spontaneous

contractile activity was visible within 24 h of plating. Within 48 h, islands of cells
maintained in growth medium were observed to contract synchronously at a rate of 80100 beats/min More prolonged culture lead to further cell spreading so that entire plates
or wells were seen to beat synchronously within 72-96 h after plating. The number of
nonmuscle cells appeared to increase only minimally during more prolonged incubation
of these dense cultures maintained in nutrient-rich, serum-free medium.

2. Up-regulation of SERCA2 Gene Expression by Inhibition of Contractile
Activity
a). Up-regulation of SERCA2 mRNA and protein levels by verapamil. To determine

whether the inhibition of contractile activity regulates SERCA2 mRNA levels in primary
cultures of neonatal ventricular myocytes, spontaneous contractile activity was
completely inhibited by adding the L-type calcium channel blocker verapamil ( 10 µM, 48
h) to the serum-free culture medium. Verapamil arrest produced cardiac myocyte atrophy,
as evidenced by a significant decrease in total cellular protein and total protein/DNA ratio
(Table 6). Furthermore, verapamil treatment (10 µM, 48 h-72 h) also decreased MHC
content, and the percentage of the total MHC that was

MHC-~,

as described in a previous

paper ( Qi et. al, 1994a).
The effects of verapamil treatment (10 µM, 48 h) on mRNA levels encoding MHC-a,
MHC-~

and SERCA2 were determined by Northern blotting, as depicted in the
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representative Northern blots presented in Figure 10. Quantitative analysis of 6 separate
Northern blotting experiments is depicted in Figure 11. In correlation with the changes in
MHC isoenzyme protein levels, MHC-a mRNA levels were increased to 200±24% of
control (n=6, P < 0.05 by paired t-test), whereas MHC-~ mRNA levels was reduced to
10±3% of control (n=6, P < 0.05 by paired t-test) (Figures 10 and 11). These results are
similar to those previously described (Samarel and Engelmann, 1991) and emphasize a
switch from

MHC-~

to MHC-a induced by verapamil which is opposite to that which

occurred during the progression of pressure overload-induced L VH in vivo. As seen in
Figure 10 and 11, SERCA2 mRNA levels were also significantly increased to 166±10%
of control (n=6, P < 0.05 by paired t-test). The effect of verapamil on SERCA2 protein
levels was also examined by Western blotting after 72 h incubation with verapamil ( 10
µM). As shown in Figure 12, the verapamil-induced increase in SERCA2 mRNA levels
was accompanied by a significant increase in SR Ca ATPase protein levels (164±20% of
control, n=6 for both groups, P < 0.05 by paired t-test; Bassani et. al, 1994).

r
95

TABLE6
Effect of Verapamil on Growth of Neonatal Rat Heart Cells

<3 (n=1'7}

V (n=l'i}

Total Protein (µg/mg)

315±15

205±15*

Protein/DNA (µg/µg)

52±1

44±2*

Total MHC (µg/dish)

15±1

7±1*

% ofMHC-B

37±2

14±1 *

Neonatal rat ventricular myocytes were maintained (72 h) in standard culture medium (C)
or medium supplemented with 10 µM verapamil (V). Cells were harvested by either
perchloric acid precipitation for analysis of total protein and DNA, or SDS-lysis for
analysis of MHC content.

Data are rnean±SEM of duplicate 35 mm dishes of each

treatment group from 17 different cell isolations. * P < 0.05 by paired t-test.
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SERCa2

4.2 kb

a-MHC

7.2 kb

~-MHC

7.2 kb

GAPDH

1.4 kb

Figure 10: Northern blots for SERCA2, MHC-a, and MHC-~ mRNA levels in
contracting and verapamil arrested cells. Neonatal rat ventricular myocytes were
maintained (48 h) in standard culture medium (Contracting) or medium supplemented
with 10 µM verapamil (Verapamil-arrested). Total RNA was isolated and equal amounts
(lOµg) of RNA were separated on 1% agarose gels and transferred to a nylon membrane.
The filter was sequentially hybridized with 32P-labeled cDNAs and oligonucleotide
probes specific for SERCA2, MHC-a, MHC-~ and GAPDH genes. Numbers to the right
indicate the size of the transcripts in kb. Constitutively expressed GAPDH mRNA levels
were used to indicate equality of RNA loading.

97

300

I
-

-"'>

250

...I

200

I Control
V(10µM)

*

CD
CD

<C

z

a:
E

-.....

150

0

100

0

"-

c

0

....0
(fl

50

0

~-----

MHC-a

MHC-~

SERCA2

Figure 11: Effects of veraparnil arrest on mRNA levels in cultured neonatal rat
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Total RNA was isolated for Northern blotting analysis. The data were obtained from 6
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Figure 12: Veraparnil induced up-regulation of SERCA2 protein levels. Neonatal rat
ventricular myocytes were maintained in serum-free growth medium in the absence (C) or
presence of 10 µM veraparnil (V) for 72 h. SERCA2 protein levels were analyzed by
Western blotting. The intensities of the bands are normalized as percent of that in C
cells. Data are the mean±SEM from 6 individual experiments.
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b). UP-regulation of SERCA2 mRNA levels by KCl and BDM. An obvious problem to
detennine the mechanism of veraparnil induced up-regulation of SERCA2 rnRNA levels is
the fact that veraparnil not only affects contractile force and amplitude but also eliminates
[Ca2+]i transients in these cultured cells (Barry et al., 1985). To determine whether upregulation of SERCA2 rnRNA levels resulted from the inhibition of contractile activity or
alterations in [Ca2+]i, primary cultures of neonatal rat ventricular myocytes were maintained
(48 h) under control conditions (C) or in the presence of 10 µM veraparnil (V), 50 rnM KCl
(KCl) or varying concentration of BDM (5, 7.5 and 10 rnM).

Like veraparnil, high

concentration of KCl (50 rnM) completely inhibited spontaneous contractile activity. Based
upon visual observation of the cultures, BDM at a concentration of 5 rnM appeared to
reduce both the amplitude and frequency of contractions. The cells were arrested with
occasional spontaneously contractile activity in the presence of 7.5 rnM BDM, and were
quiescent in the presence of 10 rnM BDM. As seen in Figure 13, Northern blot analysis
revealed that V, KCl, and BDM all down-regulated MHC-P and up-regulated SERCA2
mRNA levels. Of note, BDM treatment also appeared to decrease GAPDH rnRNA levels
for unknown reasons. Therefore, the rnRNA levels encoding MHC-P and SERCA2 in this
experiment were normalized to 18S rRN A levels. Of note, none of the arresting agents at
the concentrations used in present study appeared to affect cell viability, as assessed by
visual inspection of cultures for cell detachment, or loss of perchloric acid-precipitable
DNA per well with time (Samarel, et al., manuscript in preparation). Quantitative analysis
of 3 individual Northern blotting experiments is depicted in Figure 14, which demonstrates
that each of the arresting agents increased SERCA2 rnRNA levels, and decreased MHC-P
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rnRNA levels relative 18S rRNA. In summary, these results suggest that changes in
2

mechanical activity rather than changes in [Ca +]i regulate SERCA2 mRNA levels.
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Figure 14: Quantitative analysis of SERCA2 and MHC-B mRNA levels in verapamil,
KCl and BDM treated neonatal myocytes. Neonatal rat ventricular myocytes were
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percent of control. Data are mean±SEM from 3 individual experiments.
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3. Regulation of SERCA2 Gene Expression by Protein Kinase C

a). PMA produces myocyte hypertrophy. Addition of PMA (200 nM, 48 h) to the
serum-free culture medium produced cardiac myocyte hypertrophy, as evidenced by a
significant increase in total cellular protein and total protein/DNA ratio (Figure 15).
These changes in protein accumulation were not dependent on contractile activity, as
PMA increased total protein and protein/DNA ratio in both spontaneously contracting and
verapamil-arrested myocytes. These data confirm previous results from this laboratory
(Samarel et al., 1992), and indicate that PMA treatment stimulates cardiac myocyte
hypertrophy in cultured neonatal rat ventricular myocytes.

b). SERCA2 mRNA levels are down-regulated during PMA-stimulated myocyte
hypertrophy. As seen in Figure 16, PMA (200 nM, 48 h) increased

MHC-~

mRNA

levels in both spontaneously contracting and verapamil-arrested neonatal myocytes. In
contrast, PMA treatment markedly down-regulated SERCA2 mRNA levels

in both

contracting and verapamil-arrested cells. None of the mRNA levels were affected by
treating either contracting or arrested myocytes with the inactive compound 4a-phorbol
(4aP, 200 nM, 48 h).

Quantitative analysis of 8-11 individual Northern blotting

experiments is summarized in Figure 17.

These results demonstrate that PMA

significantly reduced SERCA2 mRNA levels by 57% and 42% in contracting and arrested
cells, respectively. Of note, down-regulation of SERCA2 mRNA levels by PMA were
not dependent on changes in contractile activity. This was evident from the lack of a
significant interaction between the factors "PMA" and "Contraction" when the data in
Figure 17 were analyzed by 2-way ANOVA.
The sensitivity of SERCA2 mRNA levels to PMA was also examined over a broad
range (2-2000 nM) of concentrations.

As seen in Figure 18, the half-maximal

concentration for PMA-induced down-regulation of SERCA2 mRNA levels was
approximately 50 nM. None of the PMA concentrations was associated with cytotoxicity,
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as manifested by cell detachment or loss of DNA content over the 48 h observation
period.

c). Regulation of SERCA2 mRNA levels by PKC activation. In all of the preceding
experiments, myocytes were continuously exposed to varying concentrations of PMA for
48 h. Since prolonged incubation with PMA is known to cause activation, followed by
down-regulation of some PKC isoenzymes (Johnson and Mochly-Rosen, 1995.), I further
examined whether varying incubation time was associated with an increase, followed by a
decrease in SERCA2 mRNA levels. As seen in Figure 19, exposure of myocytes to 200
nM PMA for 30 min - 72 h was not associated with a significant increase in SERCA2
mRNA levels as compared to untreated, control myocytes. Of note, SERCA2 mRNA
levels in both control and PMA-treated myocytes decreased during the first several hours
of maintenance culture (PMA >control), achieving stable level only after 12-24 h.
To test whether continuous exposure of myocytes to PMA was required for SERCA2
mRNA down-regulation over a 48 h period, I compared cells treated continuously for 48
h with PMA (200 nM) (P48 h), and cells that were treated with PMA for 0.5 h, followed
by vigorously washing in HBSS to remove any traces of PMA, and maintenance culture
for an additional 47.5 h in standard culture medium (P0.5h/C47.5h). As depicted in
Figure 20, SERCA2 mRNA levels were markedly reduced in both P48 h and
P0.5h/C47.5h cells, as compared to control myocytes maintained for the entire 48 h
culture period in the absence of the drug.
To further ascertain the role of PKC-dependent signal transduction pathway(s) in the
regulation of SERCA2 mRNA levels, neonatal rat ventricular myocytes were incubated
with staurosporine (10 nM), a relatively selective inhibitor of PKC activity. The effects
of staurosporine (10 nM), PMA (200 nM) and their combination on SERCA2 mRNA
levels were quantitatively analyzed by Northern blotting analysis. As seen in Figure 21,
staurosporine alone significantly (P<0.05) increased SERCA2 mRNA levels as compared
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to control myocytes. The PKC inhibitor also significantly (P<0.05) blocked the PMA-

induced down-regulation of SERCA2 mRNA.

In 2 similar experiments, the highly

specific PKC inhibitor chelerythrine (4 µM) alone had no effect on SERCA2 mRNA
levels, but completely blocked PMA induced down-regulation of SERCA2 mRNA levels
(data not shown).

d). PMA reduces SERCA2 protein content in neonatal rat ventricular myocytes.
Whereas PKC activation by PMA produced significant down-regulation of SERCA2
mRNA levels, I examined whether the changes in transcript levels were also accompanied
by changes in the relative concentrations of SR Ca ATPase protein, as determined by
Western blotting using a highly specific, polyclonal antibody to SR Ca ATPase. Neonatal
rat ventricular myocytes were incubated with or without PMA (200 nM) for 72 h, and
equal amounts of total cellular protein were separated by SDS-PAGE and Western
blotting. The SERCA2 antiserum detected a prominent, 110 kDa. band consistent with
the apparent molecular weight of rat SR Ca ATPase (Figure 22). Quantitative analysis of
SERCA2 protein levels in 8 separate Western blotting experiments is depicted in Figure
23. PMA treatment for 72 h significantly reduced SERCA2 protein levels to 47% of the
control cells (n=8 experiments, P< 0.0001).
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Figure 15: Effect of PMA on growth of neonatal rat heart cells. Neonatal rat ventricular
myocytes were maintained (48h) in standard culture medium (C) or medium
supplemented with 10 µM verapamil (V), or 200 nM phorbol 12-myristate, 13-acetate
(PMA) or their combination. Data are Mean±SEM of duplicate wells of each treatment
group from 6-17 different cell isolations. Effects of factors contraction ("C"), PMA, and
their interaction ("C-PMA") on these biochemical parameters were analyzed by 2-way
ANOV A. The results indicate that both PMA and contraction have significant effects on
these biochemical parameters. However, there is no interaction between the factors
"PMA" and "C", indicating that PMA increased total protein and protein/DNA ratio
independent of the contractile activity of the myocytes.
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Figure 16: PMA alters SERCA2 mRNA levels. Spontaneously contracting (C) neonatal
myocytes were maintained (48 h) in serum-free medium, or growth medium
supplemented with 10 µM verapamil (V) to produce contractile arrest. The PKC
activator phorbol 12-myristate 13-acetate (C+PMA, 200 nM) or the inactive phorbol 4-aphorbol (C+4aP, 200 nM) were also added to the culture medium of contracting or Varrested cells. Numbers to the right of each autoradiogram are the size ( in kilobases) of
each mRNA transcript.
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contracting (C) and verapamil-arrested (V) myocytes. Data were obtained from 8-11
individual Northern blotting experiments. The intensities of SERCA2 mRNA were
normalized to the intensities of GAPDH mRNA and plotted as the percentage of the value
of C cells. Data were analyzed by 2-way ANOV A, which indicated that both contractile
activity and PMA significantly altered SERCA2 mRNA levels. However, there was no
interaction between the factors "PMA" and "C", indicating that PMA decreased SERCA2
mRNA levels independent of the contractile activity of the myocytes.
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Figure 19: Time-dependent changes in SERCA2 mRNA levels in control and PMA-treated cells. Total RNA was isolated at 0.5,
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Figure 20: Prolonged exposure to PMA is not necessary for SERCA2 mRNA down-regulation. Neonatal rat ventricular myocytes
were maintained in serum-free growth medium for 48 h (C), growth medium containing 200 nM PMA for 48 h (P48h) or growth
medium containing 200 nM for 0.5 h followed by vigorous washing and maintenance culture for an additional 47.5 h in standard
culture medium (P 0.5h/C47.5h). Total RNA (10 µg) was subjected to Northern blotting and sequentially hybridized with 32Plabeled cDNA probes specific for SERCA2 and GAPDH mRNAs.
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Figure 21: Effects of PMA and staurosporine on SERCA2 mRNA levels. Neonatal rat
ventricular myocytes were maintained for 48 h in serum-free medium (C), medium
containing 200 nM PMA (PMA), medium containing 10 nM staurosporine (STAURO) or
medium containing both 200 nM PMA and 10 nM STAURO (P+S). The intensities of
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levels and plotted as percent of the value in C cells. Data are the means±SEM of 3
experiments.
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Figure 22: Western blot for SR Ca ATPase protein levels. Neonatal rat ventricular myocytes were maintained in serum-free
growth medium in the presence (PMA) or absence (C) of 200 nM PMA for 72 h. The cells were harvested and equal amounts of
cellular protein (40µg) were separated by SDS-polyacrylamide gel electrophoresis, transferred to nitrocellulose by electroblotting,
and probed with specific antiserum to rat SERCA2. The bands were detected by ECL technique. Depicted in the figure are
Western blots from 3 different experiments. The arrow on the left indicates the apparent molecular weight in kilodotons.
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Figure 23: PMA induced down-regulation of SERCA2 protein levels. Neonatal rat
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cells. Data are the mean±SEM from 8 individual experiments.
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C. TRANSCRIPTIONAL VS. POST-TRANSCRIPTIONAL REGULATION OF
SERCA2 GENE EXPRESSION

1. Transcriptional Regulation of SERCA2 Gene Expression.

a). PCR Cloning of the SERCA2 Promoter. I used a proximal promoter-reporter
gene construct to analyze the effects of verapamil and PMA on the rate of SERCA2 gene
transcription. A PCR-based cloning technique was used to obtain a DNA fragment from
the 5' untranslated region of rat SERCA2 gene. The PCR product was analyzed on an
agarose gel, which revealed a single amplification product corresponding to the expected
length of the fragment based upon the previously published sequence of the rat gene
(Figure 24). I subsequently sequenced this 616 bp PCR product in both directions using
the dideoxy chain termination method.

My sequence was identical to the promoter

sequence described by Hartong et al (1991) except for 4 base substitutions (Figure 25).
This 616 bp DNA fragment was successfully subcloned into the promoterless luciferase
expression plasmid (pluc), yielding a 6.4 kb promoter-reporter gene construct termed
pSERCA-luc (Figure 26).

b). PMA changes the transcription rate of SERCA2 gene expression. A transient
transfection assay was then used to determine whether verapamil or PMA altered the rate
of SERCA2 gene transcription. I transfected cultured neonatal rat ventricular myocytes
with pSERCA-luc and a constitutively expressed reporter plasmid (pRSVlacZ).
pRSVlacZ, an expression plasmid containing the bacterial lacZ gene encoding

~

galactosidase driven by the Rous sarcoma virus promoter, was used to control for
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differences in transfection efficiency. Following lipofection, the cells were maintained
(48 h) in standard growth medium, or growth medium containing verapamil (10 µM),
PMA (200 nM) or their combination. Luciferase and B-galactosidase CB-gal) activities
were measured immediately after harvesting the cells.

Both the SERCA2 promoter-

reporter gene construct (pSERCA-luc) and the reference plasmid (pRSVlacZ) were highly
expressed in cultured myocytes.

Luciferase activity in the cells transfected with

pSERCA-luc was 2000-4000 times greater than that in the cells transfected with the
promoterless pluc plasmid, indicating that pSERCA-luc has very high promoter activity
in these cells. As shown in Figure 27, verapamil treatment had no effect on normalized
luciferase activity. In contrast, PMA treatment significantly (n=9 experiments; P < 0.05)
increased normalized luciferase activities in both contracting and verapamil-arrested cells
(2.2±0.2 and 1.6±0. l fold, respectively). These results indicated that the verapamil-and
PMA-induced changes in SERCA2 mRNA levels were not primarily regulated at the
transcriptional level.

2. Effects ofVerapamil and PMA on SERCA2 mRNA Stability.

Act-D mRNA stability assays were then used to determine whether verapamil or PMA
affected the stability of SERCA2 mRNA. The neonatal rat ventricular myocytes were
maintained in growth medium in the absence or presence of verapamil ( 10 µM) or PMA
(200 nM) for 24 h. The cultures were then exposed to the RNA synthesis inhibitor
actinomycin-D (act-D, 5µg/ml) for an additional 0, 12 and 24 h. As seen in Figure 28,
SERCA2 mRNA levels in control myocytes were only reduced by approximately 20%
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after 24 h exposure to Act-D, indicating that previously transcribed SERCA2 mRNA was
relatively stable in these culture. Nonlinear regression analysis of these data revealed an
apparent half-life of SERCA2 mRNA in control myocytes of approximately 63 hours. In
contrast, SERCA2 mRNA levels in PMA-treated myocytes were reduced by over 50%
within 24 h of Act-D exposure, corresponding to an apparent half-life of approximately
23 hours. Using a similar analysis, SERCA2 mRNA levels in verapamil treated cells
,,'

appeared very stable over the time range of my observation (t 112 > 600 h).
I interpret these results as indicating that the verapamil induced up-regulation of
SERCA2 gene expression in cardiac myocytes results from the stabilization of SERCA2
mRNA. On the other hand, down-regulation of SERCA2 gene expression by PMA was
at least in part the result of a significant reduction in the half-life of this transcript.
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600bp ......

616 bp

lOObp ......

Figure 24: The 616 hp PCR product. To estimate the size of the PCR product, the PCR
reaction mixtures were loaded onto a 1.5 % agarose gel. Line 1 is a 100 hp ladder DNA
molecular weight standard, Line 2-5 are portions of the PCR reaction mixture. Numbers
to the left indicate the size the DNA fragments within the standard. Number to the right
indicates the estimated molecular weight of the PCR product.
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Figure 25: Comparison of the PCR product sequence with SERCA2 promoter sequence.
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Figure 26: SERCA2 promoter and promoterless luciferase gene construct plasmid.
Hindlll and Ncol are the unique restriction enzyme sites in the promoter and plasmid.
The numbers are bases relative to the position of the SERCA2 gene transcription start
site. + 1 is the transcription start site for SERCA2 gene.
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Figure 27: PMA increased SERCA2 rnRNA transcription rate in spontaneously
contracting (C) and verapamil arrested (V) cells. Neonatal rat ventricular myocytes were
transfected with the promoter-reporter gene construct plasmid, pSERCA-luc, and the
control plasmid, pRSVlacZ. The cell cultures were then maintained in growth medium in
the absence or presence of 10 µM verapamil or 200 nM PMA for an additional 48 h. The
cells were harvested for the measurement of luciferase and ~-gal activities. Luciferase
activity was normalized to ~-gal activity and expressed as percent of control (contracting)
cells. Data are Mean±SEM from 9 experiments. Friedman repeated measures analysis of
variance on ranks test followed by Student-Newman-Keuls test were used for statistical
comparisons of the multiple groups. * P< 0.05 vs C, + P < 0.05 vs V.
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Figure 28: Effects of verapamil and PMA on SERCA2 mRNA stability. The relative
stability of SERCA2 mRNA in control, verapamil and PMA-treated cells was assessed
following treatment of myocytes with actinomycin D (Act-D). Neonatal myocytes were
maintained in serum-free growth medium (Control), medium supplemented with 200 nM
PMA (PMA) or medium containing 10 µM verapamil (Verapamil) for 24 h. Act-D (5
µg/ml) was then added, and the cells maintained for an additional 0, 12, or 24 hat which
times total RNA was isolated and analyzed by Northern blotting with probes specific for
SERCA2 mRNA and 18S rRNA. Data are normalized to the ratio of SERCA2
mRNA/18S rRNA observed at time 0 of control, PMA or verapamil treated cells,
respectively, and plotted as· a function of time. Data are the means±SEM of 4 different
experiments.

CHAPTERV
DISCUSSION

A. DO CHANGES IN SERCA2 GENE EXPRESSION AFFECT CARDIAC
PERFORMANCE DURING LVH PROGRESSION?

1. Adult Rat Abdominal AoC Model and Hemodynamic Measurements.

In my dissertation studies, I used a rat abdominal AoC model to examine whether

changes in SERCA2 gene expression affected cardiac performance during LVH
progression. This model closely mimics chronic pressure overload hypertrophy in humans
since coarcation of the abdominal aorta of the juvenile rat produces a relatively gradual
onset of sustained hypertension, thus minimizing acute myocardial injury. My results
demonstrate that abdominal AoC produced sustained hypertension and LVH, as
evidenced by a marked elevation in the L V/body weight ratio. In agreement with others
(Mercadier et al., 1991), the present study also shows that pressure overload LV was
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accompanied by a switch in MHC isoenzyme predominance (i.e. from MHC-a to MHC-

p) which is characteristic of the LVH phenotype.
The current literature does not provide direct evidence for a causative role for
SERCA2 down-regulation in the diastolic dysfunction that accompanies pressure
overload hypertrophy, due to the lack of serial hemodynamic measurements correlated
with alterations in SERCA2 gene expression. This gap in our knowledge was addressed
in the present study, in which in vivo hemodynamic measurements of cardiac function
were obtained during the progression of LVH.

Systolic function was evaluated by

+dP/dtmruo and CI. Maximal -dP/dt (-dP/dtmax), (-dP/dtmax)IMAP, and
indices of cardiac relaxation.

't

were used as

LVEDP was also used as an index of overall cardiac

performance. As seen in Table 5, +dP/dtmax. and CI were not significantly altered in
either 8 wk and 16 wk banded animals, indicating that isovolumic systolic function was
relatively normal despite increased afterload and LVH.

In contrast, banded rats

demonstrated abnormalities in diastolic function, especially at 16 weeks. The -dP/dtmax
was reduced in both 8 and 16 wk banded rats; however, statistically significant
differences were not reached. Since -dP/dt is dependent on the peak aortic pressure rather
than on the rate of ventricular pressure decline (Lorrell, 1991), (-dP/dtmax)IMAP was used
to minimize the effect of afterload on -dP/dt as previously described (Burgess et al.,
1995). In the present study, significantly reduced (-dP/dtmax)IMAP was an indication of
slowed cardiac relaxation in both 8 and 16 wk banded rats (Table 5). Furthermore, one of
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the most accurate measures of relaxation in vivo is the time constant for isovolumic
relaxation (t). It has been widely used in many studies for a review see Gilbert and
Glantz, 1989). Because the time course for isovolumic pressure decline begins after
aortic valve closure,

't

is relatively independent of peak aortic pressure and peripheral

factors which determine the impedance to ventricular ejection (Weiss et al, 1976). In the
present study, prolongation of 't indicated impaired cardiac relaxation occurred in 16 wk
pressure overloaded hearts (Table 5). However, the 't values in 8 wk banded rats were not
statistically different from that in sham rats due to the large variability between
experimental animals. Nevertheless, the

't

values in sham rats were comparable with

other studies (Litwin et al., 1990). In addition, LVEDP was normal in 8 wk banded rats,
but was significantly (P< 0.01) elevated in 16 wk banded animal. These results indicate a
gradual development of pressure overload hypertrophy from compensated L VH (8 wk
banded rats with normal LVEDP) to a transitional phase between compensated LVH and
CHF (16 wk banded rats with markedly elevated LVEDP). As seen in Figure 4,
LVEDP were not changed by acute constriction of the abdominal aorta.
indicate that

't

't

and

These data

and LVEDP are insensitive to changes in afterload per se, but reflect

intrinsic changes in cardiac structure or function that developed over time.

2. Could the Decline in Diastolic Function During Pressure Overload LVH
Result From Decreased SERCA2 Gene Expression?
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Down-regulation of SERCA2 mRNA levels has been reported in pressure overload
hypertrophied and failing hearts in both patients and experimental animal models
(Komuro et al., 1989, Arai et al., 1993, Hasefuss et al., 1994). It has been suggested that
down-regulation of SERCA2 gene expression may be the most important contributor to
the relaxation abnormality during pressure overload hypertrophy and CHF (Schwartz et
al, 1992).

However, a cause-and-effect relationship between altered mechanical

properties and SERCA2 gene expression has not been clearly established. In the present
study, I examined both SERCA2 mRNA and protein levels in two different stages
(compensated LVH and the transitional phase between compensated LVH and HF) of
chronic pressure overload hypertrophy in the rat. The results show that SERCA2 mRNA
levels were markedly down-regulated in compensated LVH (8 wk banded rats), and
continued to decline as LV cardiac performance deteriorated.

Importantly, reduced

SERCA2 gene expression occurred in the absence of hemodynamic changes consistent
with severe cardiac decompensation and CHF. These data support the notion of Feldman
et al. (1993) that reduced SERCA2 mRNA levels may be a predictive marker of the
transition from compensatory hypertrophy to HF in the pressure overloaded heart.
However, they also indicate that time is a very important factor. Nevertheless, SERCA2
protein levels were not reduced in 8 wk banded rats, despite a prolongation in myocardial
relaxation.

These data argue against a significant contribution of SERCA2 down-

regulation to the subtle alterations in diastolic function observed in 8 wk banded rats.
Despite a normal concentration of SR Ca ATPase protein in 8 wk banded animals, the
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reduction in the number of SR Ca

2

+

pumps in 16 wk hypertensive animals did correlate

with the marked increase in LVEDP and the significant prolongation of

't.

These data

indicate down-regulation of the SERCA2 gene may indeed play an important role in the
progressive deterioration of LV performance over time.

The disparity between SERCA2 mRNA and protein levels at 8 and 16 weeks suggests
that this integral membrane protein possesses a very long half-life in the hypertrophied
LV myocardium, and the effects of decreased SERCA2 synthesis required many weeks to
become manifest. Alternatively, it is conceivable that an increase in the efficiency of
protein synthesis that accompanies pressure overload (Nagai et al., 1987) could partially
compensate for a reduction in the steady-state level of SERCA2 mRNA, producing no
significant change in the amount of SERCA2 protein synthesis until levels of this
transcript were markedly reduced. It is also conceivable that reduced SR Ca2+ pump
activity (due to changes in the amount or phosphorylation state of phospholamban,
ATPase availability or other regulatory factors) rather than reduced numbers of SR Ca2+
pumps contributed to slowed relaxation in 8 wk banded animals. Future studies are
required to evaluate these possibilities.
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3. Could The Decline in Diastolic Function During Pressure Overload LVH
Result From Changes in the cardiac ECM?
As discussed by Tsutsui et al. (1993), the velocity of relaxation is dependent upon
both intrinsic restoring forces (i.e. the potential energy that is produced by the
deformation occurring during contraction and that is released during relaxation) and the
rate of myocardial inactivation.

It has been suggested that ECM remodeling and

interstitial fibrosis may alter the elastic recoil properties of hypertrophied ventricular
tissue (Weber et al., 1993). Thus changes in the concentration or composition of ECM
components may play a role in altered cardiac relaxation in cardiac hypertrophy and
failure. In fact, increased myocardial passive stiffness can precede the development of
systolic dysfunction during pressure-overload-induced LVH (Weber et al., 1993). In the
experimental model of pressure overload used in this study (Eleftheriades et al., 1993),
increased Type I collagen gene expression, replacement fibrosis and increased myocardial
stiffness are prominent features associated with LV diastolic dysfunction, despite
relatively normal isovolumic systolic performance 16 wk after AoC. Increased LV total
collagen content, and a decrease in the ratio of Type ill to Type I collagen gene
expression were also observed in this model (Eleftheriades et al., 1993). Furthermore,
Burgess et al. (1995) recently demonstrated that Sprague-Dawley rats with unilateral renal
ischemia and 10 wk of sustained hypertension developed a similar degree of slowed
myocardial relaxation as was observed in the present study, again without impairment of
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LV systolic function. It is interesting to speculate whether these animals would have
eventually developed LV dilatation and overt signs of systolic dysfunction, as was
observed in subsets of 18-24 mo old SHR (Boluyt et al., 1994; Conrad et al., 1995),
Fisher 344 rats 8 months after renal artery constriction (Capasso et al., 1990) and Wistar
rats 20 wk after ascending aortic banding (Feldman et al., 1993). Nevertheless, the rather
subtle alterations in myocardial relaxation observed in our 8 wk hypertensive animals
were temporally related only to the presence of L VH and disproportionate collagen
accumulation, and not to changes in the number of SR Ca2+ pumps or changes in myosin
composition. Conversely, worsening cardiac function at 16 wk was not associated with a
further increase in LV mass or fibrillar collagen content, suggesting that the progressive
impairment in diastolic function over time was caused by additional factors.

As

discussed above, down-regulation of SERCA2 gene expression may have contributed to
the further deterioration of LV diastolic function, even though it was not responsible for
the impaired cardiac relaxation observed in 8 wk banded animals.

4. Could The Decline in Diastolic Function During Pressure Overload LVH
Result From The Myosin Isoenzyme Switch?
Myocardial inactivation is determined by the biochemical processes leading to the
detachment of crossbridges, the reduction in a rate of crossbridge cycling, and a decline in
[Ca2+]i (Tsutsui et al., 1993). A switch in MHC isoenzymes has been shown to affect the
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rate of crossbridge detachment and the overall rate of crossbridge cycling, thereby
reducing the rate of inactivation (Brutsaert and Sys, 1989). Therefore, the decline in
diastolic function during pressure overload LVH may be related to the change in the
expression of MHC-~ in cardiac myocytes. However, I observed a reduction in the rate
of myocardial relaxation (as assessed by the normalized -dP/dt and possibly 't) prior to a
major change in the relative concentration of

MHC-~.

MHC-~

was the predominant

MHC isoenzyme expressed in LV myocytes of 16 wk banded animals. These results
indicate that a switch in MHC isoenzymes was not responsible for the relaxation
abnormalities observed in 8 wk banded animals. However, the isoenzyme switch may
have contributed to the deterioration in cardiac performance in 16 wk banded animals.

5. Conclusions

Chronic pressure overload produced LVH and a progressive deterioration in LV
function. The slowed cardiac relaxation in compensated LVH (8 wk banded rats) did not
appear to result from down-regulation of SERCA2 gene expression. Other factors such
as remodeling of the cardiac ECM, or a decrease in SR Ca2+ATPase activity (without a
reduction in the number of SR Ca pumps) may be responsible for the relaxation
abnormality observed during the compensated phase of pressure overload LVH. Reduced
SERCA2 mRN A levels preceded the onset of overt cardiac dysfunction, indicating that
down-regulation of SERCA2 gene expression may be a useful marker to predict the
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ultimate development of cardiac dysfunction. Furthermore, decreased SERCA2 mRNA
and protein levels in 16 wk banded rats suggest that down-regulation of SERCA2 gene
plays an important role in the deterioration of LV function during the progression of
pressure overload LVH. Therefore, it is very important to determine the intracellular
mechanisms responsible for SERCA2 down-regulation during LVH progression, and to
elucidate the specific molecular events responsible for progressive diastolic dysfunction
in the pressure overloaded heart.

B. REGULATION OF SERCA2 GENE EXPRESSION IN PRIMARY CULTURES
OF NEONATAL MYOCYTES.

The signal transduction pathways involved in the down regulation of SERCA2
mRNA during pressure overload hypertrophy and CHF are undefined.

It has been

demonstrated that mechanical load is a very important trigger for induction of pressure
overload LVH. A growing body of evidence has shown that PKC activation is involved
in the gene regulation in in vitro model of cardiac hypertrophy induced by mechanical and
hormonal stimuli. More recently, activation of PKC isoenzymes in cardiac tissues has
been reported in several type of cardiac hypertrophy in vivo (review see Chapter II section
G-2). Therefore, the present study investigated the role of mechanical activity and PKC
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activation in the regulation of SERCA2 gene expression in primary cultures of neonatal
rat ventricular myocytes.

1. Cell Culture Model.

A major difficulty in defining the signaling mechanisms responsible for alterations in
cardiac myocyte gene expression during hemodynarnic overload has been the limited
ability to manipulate and control the complex in vivo physiology of the hypertrophic
process. Thus, a critical advance in the study of the mechanisms of myocyte hypertrophy
has been the development of techniques for the long-term culture of neonatal and adult
cardiac myocytes. In comparison to the whole animal study, the use of cultured cells not
only reduced the variables but also reduced animal usage and the time frame for the
investigation. Accumulated evidence has demonstrated that several major features of
pressure overload hypertrophy in vivo can be simulated in primary cultures of neonatal rat
ventricular myocytes after stimulation with defined agonists (Chien et al., 1991).
Therefore, it is likely that the hypertrophic response in both agonist-stimulated cultured
cells and hemodynarnically overloaded myocardium in vivo share common signaling
mechanisms. However, it should be pointed out that data obtained from cultured neonatal
cardiac myocytes may not always correlated with mature cardiac myocyte function in vivo
because of the developmental differences as well from the effects of culture conditions.
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To study the effects of mechanical load on cardiac hypertrophy, three types of cell
culture model systems have been widely used. They are 1) spontaneous contraction of
primary cultured neonatal rat ventricular myocytes as compared with contractile arrested
cells (produced by either membrane depolarization or L-type Ca channel blockade)
(McDermott et al., 1985; Marino et al., 1987; McDermott and Morgan, 1989; Samarel
and Engelmann, 1991); 2) electrically stimulated contractile activity (Johnson et al.,
1994); and 3) passive stretch of neonatal rat myocytes cultured on elastic membranes
(Komuro et al, 1991).

McDermott et al. (1985) have hypothesized that cellular

shortening and lengthening during contraction and relaxation of neonatal rat myocytes
attached to a rigid substratum may partially mimic the physical stimuli produced during
both passive and active tension development in the intact tissue. In the present study,
spontaneous contractile activity in primary cultured neonatal rat ventricular myocytes
were arrested by Ca channel blockade, membrane depolarization or dissociation of E-C
coupling. The various methods of producing contractile arrest not only inhibited the
growth of neonatal cardiac myocytes in culture (Table 6) but also produced a genetic
phenotype that was opposite to that found in cardiac hypertrophy in vivo (e.g. downregulation of MHC-~ and up-regulation of SERCA2 gene expression (Figure 11) ).

Direct activation of PKC by PMA has been used by many investigators to study the
signal transduction pathways involved in cardiac myocyte hypertrophy. In concurrence
with others (Fuller and Sugden, 1989; Dunmonn et al., 1990; Samarel and Engelmann,
1991; Allo et al., 1991), the present study demonstrated that primary cultured neonatal rat
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ventricular myocytes treated with PMA reproduced some features of the hypertrophic
response to pressure overload in vivo such as increased protein content per cell without
proliferation (as evidenced by increase in total protein and total protein/DNA ratio
without an increase in DNA content) (Figure 15); and up-regulation of "fetal-type"
contractile protein gene expression (e.g., MHC-P; Figure 16). Therefore, PMA induced
cardiac myocyte hypertrophy was used in the present study to examine the role of PKC
activation in the regulation of SERCA2 gene expression.

2. Contractile Arrest by Verapamil Up-regulates SERCA2 Gene Expression

In primary cultured neonatal rat ventricular myocytes, 10 µM of verapamil completely
blocks Ca2+ entry via the L-type Ca2+ channel and eliminates phasic [Ca2+]i transients and
mechanical activity (Figure 29, Ojamaa et al., 1995).
contractile

activity

with

verapamil

caused

Inhibition of spontaneous

significant

myocyte

atrophy

and

disproportionately reduced the intracellular content of a specific contractile protein,
namely MHC-P (Samarel and Engelmann 1991, and this work). In the present study,
contractile arrest by verapamil significantly up-regulated SERCA2 gene expression at
both the mRNA and protein levels. The present study also indirectly addressed the
relationship between SERCA2 gene expression and myocyte growth.

Of note, the

coordinate increase in SERCA2 mRNA and protein levels in verapamil-arrested myocytes
was considerably greater than the decrease in total RNA and total protein per cell,
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indicating that contractile arrest caused a specific increase in SERCA2 gene expression.
Simultaneously, in the same experimental model, we (Bassani et al., 1994b) evaluated SR
Ca uptake in both control and verapamil-treated cells by measuring the t 112 for [Ca2+]i
decline during twitches induced by cell depolarization in high K+ and Ca2+ solution (Ktwitch).

Since the main mechanism responsible for cell relaxation and [Ca]i decline

during a K-twitch is the SR Ca uptake. In this case the Na-Ca exchanger is inhibited and
the other mechanisms (mitochondrial uniporter and sarcolemmal Ca pump) are much too
slow to compete with the SR Ca ATPase in removig Ca from the cytosol (Bassani et al,
1994a). As summarized in Figure 30, verapamil arrest induced a marked increase in SR
Ca2+ uptake rate in parallel with the increases in SERCA2 mRNA and protein levels. The
simplest interpretation of this result is that there is an increase in the number of SR Ca
pumps, with concomitant increase in Ca transport by the SR Ca pump. These results
indicate that SR Ca ATPase protein levels are regulated at least partly at pretranslational
levels.
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3. Changes in Contractile Activity Rather Than Alterations in [Ca2+]i Regulate
SERCA2 Gene Expression.
Verapamil, KCl and BDM were used in the present study to determine whether
changes in mechanical activity or alterations in [Ca2+]i regulate SERCA2 gene
expression. All three of these agents inhibit spontaneous contractile activity of neonatal
myocytes. However, their effects on [Ca2+]i are very different. In neonatal rat ventricular
myocytes, 10 µM verapamil completely blocks Ca2+ entry and eliminates phasic [Ca2+]i
transients.

In contrast, a high concentration (50 mM) of KCl induces membrane

depolarization and causes a tonic rise in [Ca2+]i (Figure 29). BDM modestly reduced the
amplitude of the [Ca2+]i transient (Figure 29). The present study showed that verapamil,
KCl (50 mM) and BDM (10 mM) completely arrested the cells, down-regulated MHC-B
and up-regulated SERCA2 mRNA levels despite the significant differences in [Ca2+]i.
These data indicate that contractile activity rather than changes in [Ca2+]i levels regulate
SERCA2 gene expression.

4. PKC Activation Down-Regulates SR Ca ATPase and Decreases SR Ca Uptake

a). PMA-induced myocyte hypertrophy. Recent studies have demonstrated that
pressure overload hypertrophy is associated with changes in the activity of PKC or PKC
isoenzymes (Makita and Yasuda, 1990, Gu and Bishop, 1994). However, it is difficult to
define the signaling mechanisms responsible for alterations in cardiac myocyte gene
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expression during hemodynamic overload in an in vivo study. In the present study, I
demonstrated that primary cultures of neonatal rat ventricular myocytes treated with PMA
reproduced some features of the hypertrophic response to pressure overload in vivo.
PMA treatment: (a) produced myocyte hypertrophy as evidenced by an increase in total
protein and total protein/DNA ratio (Figure 15); (b) up-regulated "fetal-type" contractile
protein gene expression (e.g., MHC-p; Figure 16); and (c) down-regulated SERCA2
mRNA and protein levels leading to prolonged [Ca2+]i decline (Qi et al. unpublished
data). Previous studies have documented that prolonged exposure to PMA (48-96 h)
increased total protein (Allo et al, 1991, Dunnmon et al, 1990) and total RNA (Allo et al.,
1991) content, and increased cell size in culture.

Therefore, PMA induced myocyte

hypertrophy has been used in the present study to investigate the role of PKC in the
regulation of SERCA2 gene expression during pressure overload hypertrophy.

b). Role of PKC isoenzymes in SERCA2 down-regulation. Although PMA treatment
produced myocyte growth and down-regulation of SERCA2 mRNA and protein levels, an
obvious question raised by the present results is whether these events were indeed due to
the activation of one or more PKC isoenzymes.

Cultured neonatal rat ventricular

myocytes express the Ca2+-dependent isoenzymes PKC-a and PKC-p, the Ca2+independent isoenzymes PKC-E and PKC-8, as well as the atypical PKC-1; (MochlyRosen et al, 1990, Puceat et al, 1994, Rybin and Steinberg, 1994).

It has been

demonstrated that PMA induces the rapid translocation of cytosolic PKC-a, p, E, and 8 to
the particulate fraction of neonatal myocytes, with little or no effect on PKC-1; (Johnson
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et al., 1995, Rybin and Steinberg, 1994). Thus, PMA stimulation produces a rather
nonselective activation of multiple myocyte PKC isoenzymes.

However, isoenzyme-

dependent differences in substrate specificity might produce differences in functional
responsiveness.

A recent study (Puceat et al., 1994) has shown that PKC-c may be

responsible for agonist-stimulated phosphorylation of the 85 kDa MARCKS protein, an
endogenous PKC-specific substrate.

In contrast, agonist-induced c-fos expression is

likely to be mediated by PKC-a or 8 (Puceat et al., 1994). Additional studies will be
required to determine which PKC isoenzyme(s) is responsible for the observed changes in
SERCA2 gene expression.

However, my results indicating that relatively specific

inhibitors of PKC block the PMA-induced down-regulation of SERCA2 mRNA levels
(Figure 20) is strong evidence that these changes were in fact related to the activation of
one or more PKC isoenzymes, and not the result of a nonspecific effect of the drug.
c). Activation vs down-regulation of PKC by PMA. It should also be pointed out that

although PMA activates the PKC isoenzymes expressed in neonatal rat cardiac myocytes,
the drug also causes the time-dependent loss of some PKC isoenzymes from the cell.
Johson and Mochly-Rosen (1995) and Puceat et al (1994) have shown that PMA causes a
transient activation and subsequent down-regulation of PKC-a,

~.

c, and 8 in these

neonatal myocyte cultures but each isoenzyme is down-regulated at a distinctively
different rate (Puceat et al, 1994, Johnson and Mochly-Rosen, 1995). As many of the
experiments in this study involved the continuous exposure of myocyte cultures to PMA
for up to 72 h, it is possible that some of the observed effects were actually due to down-
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regulation (rather than activation) of PKC isoenzyme activity by PMA. However, the
time course of PMA incubation with neonatal rat myocytes shows that there were no
significant increases in SERCA2 mRNA levels during incubation with PMA.
Furthermore, this study also showed only a brief exposure (30 min) to PMA was
sufficient to produce a significant decrease in SERCA2 mRNA levels over a subsequent
48 h period (Figure 19). Johnson and Mochly-Rosen (1995) have demonstrated that
treatment of neonatal myocytes with 100 nM PMA for 30 min caused the marked
translocation of all of the PMA-responsive, PKC isoenzymes, but caused only a partial
reduction in total PKC-a,

~,

8. Total PKC-E content (the major PKC isoenzyme present

in cultured neonatal rat myocytes) was not reduced during this time period. In fact,
activated, membrane-bound PKC-E persisted for up to 8 h during continuous exposure of
neonatal myocytes to 100 nM PMA (Puceat et al., 1994). Thus, these results indicating
that only a brief exposure to PMA was sufficient to decrease SERCA2 mRNA levels
strongly suggest that down regulation of SERCA2 mRNA was the result of activation,
rather than down-regulation of one or more PKC isoenzymes.
To further ascertain the role of PKC in the regulation of SERCA2 gene expression,
two PKC inhibitors (staurosporine and chelerythrine) were used in this study.
Staurosporine, which is the most potent general inhibitor of protein kinases, has been
widely used as a PKC inhibitor (Tamaoki et al, 1986, 1991). Although, staurosporine at
high concentrations inhibits other protein kinases including protein kinase A, low
concentration of staurosporine have been used as a relatively specific PKC inhibitor
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(Kageyama et al, 1992, Allo et al, 1992). A very recent study (Budworth and Gescher,
1995) showed that staurosporine has high potency against membrane-derived PKC.
Therefore, in the present study, a low concentration ( 10 nM) of staurosporine was used
and it blocked the PMA induced down regulation of SERCA2 mRNA levels. A more
specific PKC inhibitor chelerythrine (Herbert et al., 1990) was also used in the present
study and it showed a similar result as staurosporine.

These results along with the

similarity of results obtained by acute or chronic PMA exposure, strongly indicate that
PMA induced down regulation of SERCA2 mRNA levels was the result of activation,
rather than down-regulation of one or more PKC isoenzymes.

d). Changes in SR Ca ATPase content and function in PMA treated cells. In the
present study, I demonstrated that reduced SERCA2 mRNA levels were accompanied by
a decrease in SR Ca ATPase protein. This indicates again that SR Ca ATPase protein
levels are at least partly regulated at a pre-translational level.

Similar coordinate

decreases in SERCA2 mRNA and protein levels were observed by others in the
hypertrophied and failing adult rat heart (Komuro et al., 1989 and Studer et al., 1994). It
should be pointed out, however, that the Western blotting technique used to analyze the
number of SR Ca pumps reflected the concentration of this protein relative to the total
protein pool of the cultured cells. However, the reduction in SERCA2 protein (53%) was
considerably greater than the increase in total protein or total protein/DNA ratio (26 and
15 %, respectively). These results indicate that the reduced number of SR Ca2+ pumps
resulted from a specific decrease in the expression of SERCA2 rather than dilution. To
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further prove this conclusion, [Ca +]i decline during K-twitch was measured. As seen in
Figure31, the time to peak [Ca2+]i and the rate of decline of [Ca2+]i was slower in PMAtreated cells (Qi et al., unpublished data). These data are in excellent agreement with this
conclusion.
In summary, the present study demonstrates that activation of PKC by PMA

significantly decreased SERCA2 mRNA and protein levels in primary cultures of
neonatal rat ventricular myocytes. SR Ca ATPase levels are regulated at least partly at a
pretranslational level.

The reduction of SERCA2 mRNA and protein concentration

accounted for the decrease in SR Ca uptake and ultimately contributed to the impaired
decline in the [Ca2+]i transient of the neonatal cardiac myocyte. Thus, these data suggest
that PKC activation may play an important role in the regulation of SERCA2 gene in the
hypertrophied and failing heart.
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Figure 31: SR Ca pump in control and PMA-treated neonatal rat ventricular myocytes.
The contribution of SR Ca ATPase activity to the decline of the [Ca2+]i transient in indo1 loaded myocytes was evaluated by measuring the steady-state values of t 112 for [Ca2+]i
decline during twitches induced by cell depolarization (K-Twitch), which were obtained
by brief (100 ms) application of high K solution during perfusion with 0 Na, 0 Ca (where
Na-CaX is prevented). Measurements were obtained after a series of K-twitches at 0.5
Hz to load the SR to a steady state level. The increased time to peak and slowed [Ca2+]i
decline in the PMA-treated cell in the upper panel are typical and consistent with slowed
SR Ca uptake. In the lower panel, the data were normalized to peak [Ca2+]i = 100%, replotted, and curve fitted with exponential function to demonstrate the difference in t 112 for
[Ca2+]i decline between control and PMA-treated cells. (Data are from Qi et al., 1994 b).
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C. TRANSCRIPTIONAL VS. POST-TRANSCRIPTIONAL REGULATION OF
SERCA2 GENE EXPRESSION.

1. Regulation of SERCA2 Gene Expression at the Transcriptional Level.
As discussed previously, verapamil and PMA regulate SERCA2 gene expression at a
pretranslational level. In the present study, a relatively small fragment of the rat SERCA2
promoter (556 bp) was used to regulate the expression of a luciferase reporter in order to
analyze the effects of verapamil and PMA on SERCA2 gene transcription. The results
show that verapamil treatment did not change SERCA2 promoter activity (Figure 27). In
contrast, despite a significant reduction in SERCA2 mRNA and protein levels, PMA
treatment appeared to increase SERCA2 promoter activity as measured in a transient
expression assay. A similar promoter-reporter gene transient transfection assay has been
used to analyze muscle-specific transcription (Fisher et al., 1993, Rohrer et al., 1991,
Sukovich et al., 1993, Zarain-Herzberg et al., 1990), and thyroid hormone responsiveness
of the rat (Hartong et al., 1994, Rohrer et al., 1991) and rabbit (Zarain-Herzberg et al.,
1994) SERCA2 genes.

This upstream promoter region contains sufficient regulatory

sequences to confer transcriptional activation in muscle cells (Fisher et al., 1993, Rohrer
et al., 1991, Sukovich et al., 1993) and transactivation by T3 (Hartong et al., 1994, Rohrer
et al., 1991, Zarain-Herzberg et al., 1994). However, it is conceivable that regulatory
elements further upstream from the transcriptional start site may have altered PMA
responsiveness of the reporter gene to indicate down-regulation rather than modest
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activation, as has been suggested by Dillmann et al (1992). The same argument can be
made regarding the verapamil responsiveness of the reporter gene since a "contractile
element" may also be located further upstream. Nevertheless, it appears unlikely that the
rapid reduction in SERCA2 mRNA levels in PMA-treated cells can be explained by
alterations in endogenous gene transcription rate.

2. Regulation of SERCA2 Gene Expression by Alterations in Message Stability.
In addition to the level of transcription, I hypothesized that SERCA2 gene expression

was regulated by changes in the SERCA2 mRNA stability. To determine if verapamil or
PMA can alter mRNA stability, a pharmacological inhibitor of mRNA synthesis, Act-D,
was used in the present study to define the half-life of the SERCA2 mRNA under control
and experimental conditions. The concentration of Act-D (5 µg/ml) used in this study has
been previously shown to inhibit all transcriptional activity in primary cultured neonatal
rat ventricular myocytes (Kamitani et al, 1992, LaPointe and Sitkins, 1993). Act-D was
added after 24 h incubation with various agents, then the cells were harvested for the
measurement of SERCA2 mRNA levels at different time points. In this study, 18S rRNA
levels were used for normalization of SERCA2 mRNA levels since this study and others
have shown that GAPDH mRNA levels were decreased (Tsujino et al, 1994) and 18S
rRNA levels were relatively stable (Harrold et al., 1991) during brief Act-D treatment.
Based upon the results depicted in Figure 28, verapamil stabilized the SERCA2
mRNA transcript. This may be a contributing factor to the up-regulation of SERCA2
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mRNA levels by verapamil. In contrast, a major effect of PMA treatment on SERCA2
gene expression is to destabilize the relatively long-lived SERCA2 mRNA transcript.
The nearly 3-fold reduction in mRNA half-life must contribute to the rapid decline in
SERCA2 mRNA levels, counteracting the modest increase in SERCA2 gene transcription
(Figure 32). Interestingly, Choi et al (1991) have shown that phorbol esters increase the
turnover of a-cardiac and a-skeletal actin mRNA's in chick skeletal muscle myotubes,
perhaps by affecting the synthesis of a protein responsible for increased degradation of
specific mRNA's. Additional studies will be required to determine if PKC-dependent
signaling pathways are responsible for regulating SERCA2 mRNA stability, and to
analyze its relevant to pressure overload induced down regulation of SERCA2 during
hemodynamic overload in vivo.
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Figure 32. Hypothesized mechanisms for PMA induced down-regulation of SERCA2
mRNA levels.
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D.SUMMARY:
In this study, I produced chronic pressure overload LVH by coarctation of the
abdominal aorta and addressed the hypothesis that slowed myocardial relaxation observed
in the chronically pressure-overloaded LV resulted from reduced numbers of SR Ca2+
pumps.

Although I clearly demonstrated that pressure-overload induced LVH was

associated with abnormalities in myocardial relaxation (as indicated by changes in
normalized maximum -dP/dt and 't), these hemodynamic changes were not initially
associated with a reduction in the number of SR Ca2+ pumps. Reduced SERCA2 protein
levels were not observed in this model of pressure overload until myocardial function (as
measured by the LVEDP) was significantly impaired.

Increased LV tissue collagen

content was correlated with the cardiac relaxation abnormality that was observed in 8 wk
banded rats, indicating that ECM remodeling may be responsible for the initial relaxation
abnormality in compensated, pressure overload LVH. I speculated that other factors such
as a decrease in SR Ca2+ATPase activity (without a reduction in the number of SR Ca2+
pumps) may also contribute to the relaxation abnormality in the early stage of the
pressure overload LVH.

Nevertheless, down-regulation of SERCA2 mRNA levels

preceded the deterioration of cardiac function suggesting that down-regulation of the
SERCA2 gene may be a useful marker to predict the onset of overt cardiac dysfunction
during the development of pressure overload LVH. Furthermore, down-regulation of
SERCA2 mRNA and protein levels in 16 wk banded rats may be an important
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contributing factor in the progressive deterioration in LV function during the transition
from compensated pressure overload LVH to heart failure.
The molecular mechanisms which may be involved in the regulation of SERCA2 gene
expression during pressure overload LVH and heart failure were investigated in a cultured
neonatal rat ventricular myocyte model. Firstly, the role of mechanical activity in the
regulation of SERCA2 gene expression was studied by arresting cells with verapamil,
KCl and BDM.

Verapamil arrest increased SERCA2 mRNA and protein levels,

indicating that verapamil induced changes in SR Ca ATPase content are regulated at
pretranslational levels. SERCA2 mRNA levels were also up-regulated in KCl and BDM
arrested cells, suggesting that changes in contractile activity rather than changes in [Ca2+]i
regulate SERCA2 mRNA levels. Secondly, the role of PKC in the regulation of SERCA2
gene expression was also examined. The PKC activator PMA induced cardiac myocyte
hypertrophy and caused down-regulation of SERCA2 mRNA and protein levels. The
effect of PMA-induced down-regulation of SR Ca ATPase were blocked by PKC
inhibitors. These results indicate PKC activation down-regulates SERCA2 mRNA levels.
These data suggest that PKC activation

may play an important role in the down-

regulation of the SERCA2 gene during pressure overload.

Finally, the transient

transfection assay and Act-D message stability assay demonstrate that the changes in
SERCA2 mRNA levels by verapamil and PMA were not primarily controlled at the
transcriptional level.

Changes in SERCA2 message stability are responsible for the
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changes in SERCA2 mRNA level in these cell culture models of myocyte atrophy and
hypertrophy.
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